

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ABALOPARATIDE**

---

### **Products Affected**

- TYMLOS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ABATACEPT IV**

### **Products Affected**

- ORENCIA INTRAVENOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA.
<b>Indications</b>	All FDA-approved Indications.

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ABATACEPT SQ

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA.

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ABEMACICLIB**

---

### **Products Affected**

- VERZENIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## ABIRATERONE

### Products Affected

- abiraterone acetate*
- abirtega*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ABIRATERONE SUBMICRONIZED**

### **Products Affected**

- YONSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ACALABRUTINIB**

### **Products Affected**

- CALQUENCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: INTOLERANCE TO BRUKINSA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ADAGRASIB**

---

### **Products Affected**

- KRAZATI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ADALIMUMAB**

### **Products Affected**

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED.</p> <p>POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR</p>

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ADALIMUMAB-AATY**

### **Products Affected**

- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ADALIMUMAB-ADBIM**

### **Products Affected**

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16  
Last Updated: 06/24/2025  
Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **AFATINIB**

### **Products Affected**

- GILOTRIF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ALECTINIB**

---

### **Products Affected**

- ALECENSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ALPELISIB-PIQRAY**

---

**Products Affected**

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## AMIKACIN LIPOSOMAL INH

### Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT.
Age Restrictions	
Prescriber Restrictions	MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	INITIAL/RENEWAL: 6 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **AMIVANTAMAB-VMJW**

---

### **Products Affected**

- RYBREVANT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

# ANAKINRA

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.
<b>Required Medical Information</b>	INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. CAPS, DIRA: NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **APALUTAMIDE**

### **Products Affected**

- ERLEADA ORAL TABLET 240 MG, 60 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **APOMORPHINE - ONAPGO**

---

### **Products Affected**

- ONAPGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PA Criteria: Pending CMS Approval
<b>Required Medical Information</b>	PA Criteria: Pending CMS Approval
<b>Age Restrictions</b>	PA Criteria: Pending CMS Approval
<b>Prescriber Restrictions</b>	PA Criteria: Pending CMS Approval
<b>Coverage Duration</b>	PA Criteria: Pending CMS Approval
<b>Other Criteria</b>	PA Criteria: Pending CMS Approval
<b>Indications</b>	PA Criteria: Pending CMS Approval
<b>Off Label Uses</b>	PA Criteria: Pending CMS Approval
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **APOMORPHINE - SL**

### **Products Affected**

- KYNMOBI
- KYNMOBI TITRATION KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# APREMILAST

## Products Affected

- OTEZLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING 2 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., PUVA [PHOTOTHERAPY], UVB [ULTRAVIOLET LIGHT B], TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR MODERATE TO SEVERE PSO. BEHCETS DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). RENEWAL: MILD PSO, BEHCETS DISEASE: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. MODERATE TO SEVERE PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR MODERATE TO SEVERE PSO.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ARIMOCLOMOL**

---

### **Products Affected**

- MIPLYFFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ASCIMINIB**

### **Products Affected**

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ASFOTASE ALFA**

### **Products Affected**

- STRENSIQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ATOGEPA

## Products Affected

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# AVACOPAN

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 6 MONTHS.
<b>Other Criteria</b>	ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **AVAPRITINIB**

---

### **Products Affected**

- AYVAKIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## AVUTOMETINIB-DEFACTINIB

### Products Affected

- AVMAPKI FAKZYNJA CO-PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **AXATILIMAB-CSFR**

---

### **Products Affected**

- NIKTIMVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **AXITINIB**

---

### **Products Affected**

- INLYTA ORAL TABLET 1 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **AZACITIDINE**

---

### **Products Affected**

- ONUREG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## AZTREONAM INHALED

### Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	7 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BEDAQUILINE**

---

### **Products Affected**

- SIRTURO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 WEEKS
<b>Other Criteria</b>	PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB): SIRTURO USED IN COMBINATION WITH AT LEAST 3 OTHER ANTIBIOTICS FOR THE TREATMENT OF PULMONARY MDR-TB.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# **BELIMUMAB**

## **Products Affected**

- BENLYSTA SUBCUTANEOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BELUMOSUDIL**

---

### **Products Affected**

- REZUROCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BELZUTIFAN**

---

### **Products Affected**

- WELIREG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BENDAMUSTINE**

### **Products Affected**

- BENDAMUSTINE HCL  
INTRA VENOUS SOLUTION
- *bendamustine hcl intravenous solution  
reconstituted*
- BENDEKA
- VIVIMUSTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BENRALIZUMAB**

### **Products Affected**

- FASENRA
- FASENRA PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-2 INHIBITOR) FOR EGPA. RENEWAL: ASTHMA: 1) NO

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EGPA: 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR EGPA
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BETAINE**

---

### **Products Affected**

- *betaine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BEVACIZUMAB-ADCD**

---

### **Products Affected**

- VEGZELMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BEVACIZUMAB-AWWB**

---

### **Products Affected**

- MVASI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BEVACIZUMAB-BVZR**

---

### **Products Affected**

- ZIRABEV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## BEXAROTENE

### Products Affected

- bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BINIMETINIB**

---

**Products Affected**

- MEKTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BORTEZOMIB**

### **Products Affected**

- *bortezomib injection*
- BORUZU

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# BOSENTAN

## Products Affected

- *bosentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **BOSUTINIB**

### **Products Affected**

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# BRIGATINIB

## Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

## C1 ESTERASE INHIBITOR-HAEGARDA

### Products Affected

- HAEGARDA SUBCUTANEOUS  
SOLUTION RECONSTITUTED 2000  
UNIT, 3000 UNIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY ANGIOEDEMA (HAE): INITIAL: DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTING: C1INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CABOZANTINIB CAPSULE**

---

### **Products Affected**

- COMETRIQ (100 MG DAILY DOSE)  
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)  
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CABOZANTINIB TABLET**

---

### **Products Affected**

- CABOMETYX ORAL TABLET 20 MG,  
40 MG, 60 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# CANNABIDIOL

## Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CAPIVASERTIB**

---

**Products Affected**

- TRUQAP ORAL TABLET
- TRUQAP TABLET THERAPY PACK  
160 MG ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CAPMATINIB**

---

### **Products Affected**

- TABRECTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CARGLUMIC ACID**

### **Products Affected**

- *carglumic acid oral tablet soluble*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.
<b>Other Criteria</b>	RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CERITINIB**

---

### **Products Affected**

- ZYKADIA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CERTOLIZUMAB PEGOL**

### **Products Affected**

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK,

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>SKYRIZI, TREMFYA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: STELARA/SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJIA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL FOR PSA, PSO, AS, CD, NR-AXSPA, PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CETUXIMAB**

---

### **Products Affected**

- ERBITUX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CLADRIBINE**

### **Products Affected**

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	48 WEEKS.
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## CLOBAZAM-SYMPAZAN

### Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	LGS: 1) UNABLE TO TAKE TABLETS OR SUSPENSIONS, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF CLOBAZAM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **COBIMETINIB**

---

### **Products Affected**

- COTELLIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# CORTICOTROPIN

## Products Affected

- ACTHAR
- ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR 40 UNIT/0.5ML, 80 UNIT/ML
- CORTROPHIN

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST.
Coverage Duration	INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	Yes

Formulary ID: 25262 version 16  
Last Updated: 06/24/2025  
Effective: 07/01/2025

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## CRIZOTINIB CAPSULE

### Products Affected

- XALKORI ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **CRIZOTINIB PELLETS**

### **Products Affected**

- XALKORI ORAL CAPSULE SPRINKLE  
150 MG, 20 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT): UNABLE TO SWALLOW CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## DABRAFENIB CAPSULES

### Products Affected

- TAFINLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## DABRAFENIB SUSPENSION

### Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNABLE TO SWALLOW TAFINLAR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# DACOMITINIB

## Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DALFAMPRIDINE**

### **Products Affected**

- *dalfampridine er*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA. RENEWAL: IMPROVEMENT IN WALKING ABILITY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# DAROLUTAMIDE

## Products Affected

- NUBEQA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MHSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DASATINIB**

### **Products Affected**

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## DATOPOTAMAB DERUXTECAN-DLNK

---

### Products Affected

- DATROWAY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## DECITABINE/CEDAZURIDINE

---

### Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## DEFERASIROX

### Products Affected

- deferasirox granules*
- deferasirox oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF DRY LIVER WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF DRY LIVER WEIGHT OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL (CHRONIC IRON OVERLOAD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL (CHRONIC IRON OVERLOAD): DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DENOSUMAB-XGEVA**

---

### **Products Affected**

- XGEVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DEUTETRABENAZINE**

### **Products Affected**

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12
- AUSTEDO XR PATIENT TITRATION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DICLOFENAC TOPICAL SOLUTION**

### **Products Affected**

- *diclofenac sodium external solution 2 %*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1% TOPICAL GEL AND A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# DICLOFENAC-FLECTOR

## Products Affected

- *diclofenac epolamine external*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DIMETHYL FUMARATE**

### **Products Affected**

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DIROXIMEL FUMARATE**

---

### **Products Affected**

- VUMERITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DOSTARLIMAB-GXLY**

---

### **Products Affected**

- JEMPERLI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DRONABINOL CAPSULE**

### **Products Affected**

- *dronabinol*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D FOR THE INDICATION OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DROXIDOPA**

### **Products Affected**

- *droxidopa*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## DUPILUMAB

### Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. ATOPIC DERMATITIS (AD): AD COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR AD AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	AD, PN, CSU: PRESCRIBED OR IN CONSULTATION WITH DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST OR PULMONOLOGIST. CRSWNP: PRESCRIBED OR IN CONSULTATION WITH OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED OR IN CONSULTATION WITH GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED OR IN CONSULTATION WITH PULMONOLOGIST. RENEWAL: CSU: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: AD, CRSWNP, EOE, PN, CSU: 6 MOS, ASTHMA, COPD: 12 MOS. RENEWAL: ALL INDICATIONS: 12 MOS.
<b>Other Criteria</b>	INITIAL/RENEWAL: AD: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS OR JAK INHIBITORS FOR AD. ASTHMA: NO CONCURRENT USE WITH XOLAIR, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>EOSINOPHILIC COPD: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS OR JAK-I FOR SAME INDICATION. INITIAL: AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, OR JAK INHIBITOR). ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID. PRURIGO NODULARIS (PN): 1) CHRONIC PRURITUS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID OR CALCIPOTRIOL). EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. CHRONIC SPONTANEOUS URTICARIA (CSU): 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. RENEWAL: AD, CRSWNP, EOE: IMPROVEMENT WHILE ON THERAPY. ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF</p>

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	PRURITUS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE. CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **DUVELISIB**

---

### **Products Affected**

- COPIKTRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **EFLORNITHINE**

---

### **Products Affected**

- IWILFIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ELACESTRANT**

---

### **Products Affected**

- ORSERDU ORAL TABLET 345 MG, 86 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ELAGOLIX

## Products Affected

- ORLISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## ELRANATAMAB-BCMM

### Products Affected

- ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ELTROMBOPAG - ALVAIZ**

### **Products Affected**

- ALVAIZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LABS IN THE LAST 3 MONTHS, OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LABS IN THE LAST 3 MONTHS AND HAD A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) OR SPLEEN TYROSINE KINASE (SYK) INHIBITOR. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS OR SYK INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ELTROMBOPAG - PROMACTA**

### **Products Affected**

- PROMACTA ORAL PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN $30 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LAB TESTS IN THE LAST 3 MONTHS, OR 2) PLATELET COUNT OF LESS THAN $50 \times 10^9/L$ FROM AT LEAST 2 SEPARATE LAB TESTS IN THE LAST 3 MONTHS AND A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) OR SPLEEN TYROSINE KINASE (SYK) INHIBITOR. ALL INDICATIONS: APPROVAL FOR PROMACTA ORAL SUSPENSION PACKETS REQUIRES A TRIAL OF PROMACTA TABLET OR PATIENT IS UNABLE TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS OR SYK INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ENASIDENIB**

---

### **Products Affected**

- IDHIFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ENCORAFENIB**

---

### **Products Affected**

- BRAFTOVI ORAL CAPSULE 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ENTRECTINIB CAPSULES**

---

### **Products Affected**

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ENTRECTINIB PELLETS**

---

### **Products Affected**

- ROZLYTREK ORAL PACKET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ENZALUTAMIDE

## Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: ALL INDICATIONS: 12 MONTHS. RENEWAL: MCRPC, NMCRPC, MCSPC: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E. RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CRPC (MCRPC), NMCRPC, METASTATIC CSPC (MCSPC), NMCSPC : 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: MCRPC, NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## EPCORITAMAB-BYSP

### Products Affected

- EPKINLY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **EPOETIN ALFA-EPBX**

### **Products Affected**

- RETACRIT INJECTION SOLUTION UNIT/ML, 4000 UNIT/ML, 40000  
10000 UNIT/ML, 10000 UNIT/ML(1ML), UNIT/ML  
2000 UNIT/ML, 20000 UNIT/ML, 3000

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS LESS THAN 13G/DL. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.
<b>Other Criteria</b>	RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ERDAFITINIB**

---

### **Products Affected**

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## ERENUMAB-AOOE

### Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ERLOTINIB

## Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg,  
25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ESKETAMINE

## Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST.
Coverage Duration	INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.
Other Criteria	INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# ETANERCEPT

## Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **EVEROLIMUS-AFINITOR**

### **Products Affected**

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## EVEROLIMUS-AFINITOR DISPERZ

### Products Affected

- everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FECAL MICROBIOTA CAPSULE**

### **Products Affected**

- VOWST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 DAYS
<b>Other Criteria</b>	CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FEDRATINIB**

### **Products Affected**

- INREBIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## FENFLURAMINE

### Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	DRAVET SYNDROME: INITIAL/RENEWAL: 12 MONTHS. LGS: 12 MONTHS.
Other Criteria	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. RENEWAL: DRAVET SYNDROME: PATIENT HAS SHOWN CONTINUED CLINICAL BENEFIT (E.G. REDUCTION OF SEIZURES, REDUCED LENGTH OF SEIZURES, SEIZURE CONTROL MAINTAINED).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## FENTANYL CITRATE

### Products Affected

- fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## FEZOLINETANT

### Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) EXPERIENCES 7 OR MORE HOT FLASHES PER DAY, AND 2) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS). RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (I.E., PERSISTENT HOT FLASHES), AND 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FILGRASTIM-AAFI**

---

### **Products Affected**

- NIVESTYM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PREScribed BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FINERENONE**

---

### **Products Affected**

- KERENDIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## FINGOLIMOD

### Products Affected

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FOSCARBIDOPA-FOSLEVODOPA**

### **Products Affected**

- VYALEV SUBCUTANEOUS  
SOLUTION 12-240 MG/ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PD: INITIAL: 1) RESPONSIVE TO LEVODOPA, 2) CURRENT REGIMEN INCLUDES AT LEAST 400 MG/DAY OF LEVODOPA, AND 3) MOTOR SYMPTOMS ARE CURRENTLY UNCONTROLLED (DEFINED AS AN AVERAGE OFF TIME OF AT LEAST 2.5 HOURS/DAY OVER 3 CONSECUTIVE DAYS WITH A MINIMUM OF 2 HOURS EACH DAY). RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FREMANEZUMAB-VFRM**

### **Products Affected**

- AJOVY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FRUQUINTINIB**

---

### **Products Affected**

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **FUTIBATINIB**

### **Products Affected**

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GALCANEZUMAB-GNLM**

### **Products Affected**

- EMGALITY
- EMGALITY (300 MG DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.
<b>Other Criteria</b>	INITIAL: MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: MIGRAINE PREVENTION: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. EPISODIC CLUSTER HEADACHE: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GANAXOLONE**

---

### **Products Affected**

- ZTALMY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## GEFITINIB

### Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GILTERITINIB**

---

### **Products Affected**

- XOSPATA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GLASDEGIB**

---

### **Products Affected**

- DAURISMO ORAL TABLET 100 MG,  
25 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# GLATIRAMER

## Products Affected

- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GLP1-DULAGLUTIDE**

---

**Products Affected**

- TRULICITY SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GLP1-SEMAGLUTIDE**

### **Products Affected**

- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- RYBELSUS (FORMULATION R2)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## GLP1-TIRZEPATIDE

---

### Products Affected

- MOUNJARO SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# GOSERELIN

## Products Affected

- ZOLADEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.
<b>Other Criteria</b>	ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **GUSELKUMAB**

### **Products Affected**

- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS
- TREMFYA PEN SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR 200  
MG/2ML
- TREMFYA SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HIGH CONCENTRATION ORAL OPIOID SOLUTIONS

## Products Affected

- morphine sulfate (concentrate) oral solution 100 mg/5ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	OPIOID TOLERANT: 12 MONTHS. HOSPICE, PALLIATIVE CARE OR END OF LIFE CARE: LIFETIME.
Other Criteria	1) OPIOID TOLERANT (I.E. PREVIOUS USE OF 60 MG ORAL MORPHINE PER DAY, 25 MCG TRANSDERMAL FENTANYL PER HOUR, 30 MG ORAL OXYCODONE PER DAY, 8 MG ORAL HYDROMORPHONE PER DAY, 25 MG ORAL OXYMORPHONE PER DAY, 60 MG ORAL HYDROCODONE PER DAY, OR AN EQUIANALGESIC DOSE OF ANOTHER OPIOID) AND HAS TROUBLE SWALLOWING OPIOID TABLETS, CAPSULES, OR LARGE VOLUMES OF LIQUID, OR 2) ENROLLED IN HOSPICE OR PALLIATIVE CARE OR END OF LIFE CARE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IBRUTINIB

## Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## ICATIBANT

### Products Affected

- *icatibant acetate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY ANGIOEDEMA (HAE): DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING.
Age Restrictions	
Prescriber Restrictions	HAE: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, OR HEMATOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	HAE: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR TREATMENT OF ACUTE HAE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **IDELALISIB**

---

### **Products Affected**

- ZYDELIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IMATINIB

## Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IMATINIB SOLUTION

## Products Affected

- IMKELDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IMETELSTAT

---

**Products Affected**

- RYTELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **INAVOLISIB**

---

### **Products Affected**

- ITOVEBI ORAL TABLET 3 MG, 9 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **INFLIXIMAB**

### **Products Affected**

- *infliximab*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>MOLECULES FOR PSO. AS: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. MODERATE TO SEVERE CD: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA/SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA/SELARSDI/YESINTEK, XELJANZ, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. MODERATE TO SEVERE CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## INSULIN SUPPLIES PAYMENT DETERMINATION

---

### Products Affected

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 0.5 ML (OTC)
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM
- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- BD AUTOSHIELD 29G X 5MM
- BD AUTOSHIELD 29G X 8MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 25G X 1" 1 ML
- BD INSULIN SYRINGE 25G X 5/8" 1 ML
- BD INSULIN SYRINGE 26G X 1/2" 1 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 0.5 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE U-500
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 1 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 0.5 ML
- BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO U/F 32G X 4 MM
- BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM
- BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM
- BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM
- BD SAFETY-LOK INSULIN SYRINGE 29G X 1/2" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

- |  |  |
|--|--|
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML | • CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML      |
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML   | • CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML   |
| • BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML  | • CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML   |
| • BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML      | • CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML     |
| • BD SWAB SINGLE USE REGULAR PAD                     | • CARETOUCH ALCOHOL PREP PAD 70 %              |
| • BD SWABS SINGLE USE BUTTERFLY PAD                  | • CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML   |
| • BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML | • CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML   |
| • BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML   | • CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML   | • CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML   |
| • BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML     | • CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML     | • CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML     | • CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML   |
| • BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML       | • CARETOUCH PEN NEEDLES 29G X 12MM             |
| • CAREFINE PEN NEEDLES 29G X 12MM                    | • CARETOUCH PEN NEEDLES 31G X 5 MM             |
| • CAREFINE PEN NEEDLES 30G X 8 MM                    | • CARETOUCH PEN NEEDLES 31G X 6 MM             |
| • CAREFINE PEN NEEDLES 31G X 6 MM                    | • CARETOUCH PEN NEEDLES 31G X 8 MM             |
| • CAREFINE PEN NEEDLES 31G X 8 MM                    | • CARETOUCH PEN NEEDLES 32G X 4 MM             |
| • CAREFINE PEN NEEDLES 32G X 4 MM                    | • CARETOUCH PEN NEEDLES 32G X 5 MM             |
| • CAREFINE PEN NEEDLES 32G X 5 MM                    | • CARETOUCH PEN NEEDLES 33G X 4 MM             |
| • CAREFINE PEN NEEDLES 32G X 6 MM                    | • CLEVER CHOICE COMFORT EZ 29G X 12MM          |
| • CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML          | • CLEVER CHOICE COMFORT EZ 33G X 4 MM          |
| • CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML          | • CLICKFINE PEN NEEDLES 31G X 6 MM             |

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- |   |   |
|---|---|
| • CLICKFINE PEN NEEDLES 31G X 8 MM                  | • COMFORT EZ PEN NEEDLES 31G X 6 MM         |
| • CLICKFINE PEN NEEDLES 32G X 4 MM                  | • COMFORT EZ PEN NEEDLES 31G X 8 MM         |
| • COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML    | • COMFORT EZ PEN NEEDLES 32G X 4 MM         |
| • COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML | • COMFORT EZ PEN NEEDLES 32G X 5 MM         |
| • COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML      | • COMFORT EZ PEN NEEDLES 32G X 6 MM         |
| • COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML        | • COMFORT EZ PEN NEEDLES 32G X 8 MM         |
| • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML      | • COMFORT EZ PEN NEEDLES 33G X 4 MM         |
| • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML      | • COMFORT EZ PEN NEEDLES 33G X 5 MM         |
| • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML        | • COMFORT EZ PEN NEEDLES 33G X 6 MM         |
| • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML      | • COMFORT EZ PEN NEEDLES 33G X 8 MM         |
| • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML      | • COMFORT EZ PRO PEN NEEDLES 30G X 8 MM     |
| • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML        | • COMFORT EZ PRO PEN NEEDLES 31G X 4 MM     |
| • COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML     | • COMFORT EZ PRO PEN NEEDLES 31G X 5 MM     |
| • COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML     | • COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM |
| • COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML       | • COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM |
| • COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML    | • COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM |
| • COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML    | • COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM |
| • COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML      | • COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM |
| • COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML     | • COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM |
| • COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML     | • COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM |
| • COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML       | • COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM |
| • COMFORT EZ PEN NEEDLES 31G X 5 MM                 | • CURITY ALCOHOL PREPS PAD 70 %             |
|   | • CURITY ALL PURPOSE SPONGES PAD 2"X2"      |

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS GAUZE PAD 2"X2"
- CVS GAUZE STERILE PAD 2"X2"
- DERMACEA GAUZE SPONGE PAD 2"X2"
- DERMACEA IV DRAIN SPONGES PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD 2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5 MM
- DIATHRIVE PEN NEEDLE 31G X 6 MM
- DIATHRIVE PEN NEEDLE 31G X 8 MM
- DIATHRIVE PEN NEEDLE 32G X 4 MM
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML
- DROPLET INSULIN SYRINGE 31G X 1/4" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 1/4" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 1/4" 1 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM
- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 8 MM
- DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML
- DRUG MART UNIFINE PENTIPS 31G X 5 MM
- EASY COMFORT ALCOHOL PADS PAD
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- EASY COMFORT PEN NEEDLES 29G X 4MM
- EASY COMFORT PEN NEEDLES 29G X 5MM
- EASY COMFORT PEN NEEDLES 31G X 5 MM
- EASY COMFORT PEN NEEDLES 31G X 6 MM
- EASY COMFORT PEN NEEDLES 31G X 8 MM
- EASY COMFORT PEN NEEDLES 32G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 5 MM
- EASY COMFORT PEN NEEDLES 33G X 6 MM
- EASY GLIDE PEN NEEDLES 33G X 4 MM
- EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %
- EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML
- EASY TOUCH INSULIN BARRELS U-100 1 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY TOUCH PEN NEEDLES 29G X 12MM
- EASY TOUCH PEN NEEDLES 30G X 5 MM
- EASY TOUCH PEN NEEDLES 30G X 6 MM
- EASY TOUCH PEN NEEDLES 30G X 8 MM
- EASY TOUCH PEN NEEDLES 31G X 5 MM
- EASY TOUCH PEN NEEDLES 31G X 6 MM
- EASY TOUCH PEN NEEDLES 31G X 8 MM
- EASY TOUCH PEN NEEDLES 32G X 4 MM
- EASY TOUCH PEN NEEDLES 32G X 5 MM
- EASY TOUCH PEN NEEDLES 32G X 6 MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBECTA AUTOSHIELD DUO 30G X 5 MM
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-100 28G X 1/2" 1 ML

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EQL INSULIN SYRINGE 30G X 5/16" 1 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FIFTY50 PEN NEEDLES 32G X 6 MM
- FREESTYLE PRECISION INS SYR 30G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 30G X 5/16" 1 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 1 ML
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- |   |   |
|---|---|
| • GNP INSULIN SYRINGE 28G X 1/2" 1 ML               | • HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML    |
| • GNP INSULIN SYRINGE 29G X 1/2" 0.5 ML             | • HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML      |
| • GNP INSULIN SYRINGE 29G X 1/2" 1 ML               | • HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM            |
| • GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML            | • HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM             |
| • GNP INSULIN SYRINGE 30G X 5/16" 1 ML              | • HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM             |
| • GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML   | • HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM           |
| • GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML     | • HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM           |
| • GNP INSULIN SYRINGES 30G X 5/16" 1 ML             | • HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM           |
| • GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML | • HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM           |
| • GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML | • HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM           |
| • GNP STERILE GAUZE PAD 2"X2"                       | • HM STERILE ALCOHOL PREP PAD                         |
| • GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 0.3 ML  | • HM STERILE PADS PAD 2"X2"                           |
| • GOODSENSE ALCOHOL SWABS PAD 70 %                  | • HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML         |
| • H-E-B INCONTROL ALCOHOL PAD                       | • HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML      |
| • H-E-B INCONTROL PEN NEEDLES 29G X 12MM            | • HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM            |
| • H-E-B INCONTROL PEN NEEDLES 31G X 5 MM            | • INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM           |
| • H-E-B INCONTROL PEN NEEDLES 31G X 6 MM            | • INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM           |
| • H-E-B INCONTROL PEN NEEDLES 31G X 8 MM            | • INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM           |
| • H-E-B INCONTROL PEN NEEDLES 32G X 4 MM            | • INSULIN SYRINGE 29G X 1/2" 1 ML                     |
| • HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML  | • INSULIN SYRINGE 30G X 5/16" 1 ML                    |
| • HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML  | • INSULIN SYRINGE 31G X 5/16" 0.3 ML                  |
| • HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML    | • INSULIN SYRINGE 31G X 5/16" 0.5 ML                  |
| • HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML  | • INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX) |
|   | • INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)   |

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- |   |   |
|---|---|
| • INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)   | • LEADER UNIFINE PENTIPS 31G X 5 MM             |
| • INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)     | • LEADER UNIFINE PENTIPS 32G X 4 MM             |
| • INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML         | • LEADER UNIFINE PENTIPS PLUS 31G X 5 MM        |
| • INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML        | • LEADER UNIFINE PENTIPS PLUS 31G X 8 MM        |
| • INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML        | • LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML   |
| • INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML          | • LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML     |
| • INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC) | • LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML   |
| • INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML              | • LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML   |
| • INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML              | • LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML     |
| • INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML                | • LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML  |
| • INSUPEN PEN NEEDLES 31G X 5 MM                        | • LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML  |
| • INSUPEN PEN NEEDLES 31G X 8 MM                        | • LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML    |
| • INSUPEN PEN NEEDLES 32G X 4 MM                        | • LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML  |
| • INSUPEN PEN NEEDLES 33G X 4 MM                        | • LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML  |
| • INSUPEN SENSITIVE 32G X 6 MM                          | • LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML    |
| • INSUPEN SENSITIVE 32G X 8 MM                          | • LITETOUCH PEN NEEDLES 29G X 12.7MM            |
| • INSUPEN ULTRAFIN 29G X 12MM                           | • LITETOUCH PEN NEEDLES 31G X 5 MM              |
| • INSUPEN ULTRAFIN 30G X 8 MM                           | • LITETOUCH PEN NEEDLES 31G X 6 MM              |
| • INSUPEN ULTRAFIN 31G X 6 MM                           | • LITETOUCH PEN NEEDLES 31G X 8 MM              |
| • INSUPEN ULTRAFIN 31G X 8 MM                           | • LITETOUCH PEN NEEDLES 32G X 4 MM              |
| • J & J GAUZE PAD 2"X2"                                 | • MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML |
| • KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"              | • MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML |
| • KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"               |   |
| • KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML              |   |
| • KMART VALU INSULIN SYRINGE 29G U-100 1 ML             |   |
| • KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML           |   |
| • KMART VALU INSULIN SYRINGE 30G U-100 1 ML             |   |
| • KROGER PEN NEEDLES 29G X 12MM                         |   |
| • KROGER PEN NEEDLES 31G X 8 MM                         |   |

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- |  |   |
|--|---|
| • MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML    | • MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML                |
| • MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML | • MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)          |
| • MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML | • MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)         |
| • MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML   | • MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)          |
| • MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML | • MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)           |
| • MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML   | • MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML              |
| • MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM       | • MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML              |
| • MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM       | • MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)           |
| • MAXICOMFORT II PEN NEEDLE 31G X 6 MM           | • MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML             |
| • MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML   | • MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)        |
| • MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML     | • MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)          |
| • MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML       | • MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML               |
| • MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML       | • MONOJECT INSULIN SYRINGE U-100 1 ML                     |
| • MEDICINE SHOPPE PEN NEEDLES 29G X 12MM         | • MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)  |
| • MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM         | • MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)   |
| • MEDPURA ALCOHOL PADS 70 % EXTERNAL             | • MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)    |
| • MEIJER ALCOHOL SWABS PAD 70 %                  | • MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML        |
| • MEIJER PEN NEEDLES 29G X 12MM                  | • MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML          |
| • MEIJER PEN NEEDLES 31G X 6 MM                  | • MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC) |
| • MEIJER PEN NEEDLES 31G X 8 MM                  | • MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)  |
| • MICRODOT PEN NEEDLE 31G X 6 MM                 | • MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)  |
| • MICRODOT PEN NEEDLE 32G X 4 MM                 | • NOVOFINE AUTOCOVER 30G X 8 MM                           |
| • MICRODOT PEN NEEDLE 33G X 4 MM                 | • NOVOFINE PEN NEEDLE 32G X 6 MM                          |
| • MIRASORB SPONGES 2"X2"                         |   |
| • MM PEN NEEDLES 32G X 4 MM                      |   |

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 32G X 4 MM (OTC)
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 1 ML
- PRECISION SURE-DOSE SYRINGE 29G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 3/8" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 31G X 8 MM
- PRO COMFORT PEN NEEDLES 32G X 4 MM
- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRODIGY INSULIN SYRINGE 28G X 1/2" 1 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.3 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PURE COMFORT ALCOHOL PREP PAD
- PURE COMFORT PEN NEEDLE 32G X 4 MM
- PURE COMFORT PEN NEEDLE 32G X 5 MM
- PURE COMFORT PEN NEEDLE 32G X 6 MM
- PURE COMFORT PEN NEEDLE 32G X 8 MM

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM
- PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM
- RA ALCOHOL SWABS PAD 70 %
- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELI-ON INSULIN SYRINGE 29G 0.5 ML
- RELI-ON INSULIN SYRINGE 29G X 1/2" 1 ML
- RELION ALCOHOL SWABS PAD
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML
- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM ALCOHOL PREP PAD 70 %
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- STERILE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE-PREP ALCOHOL PREP PAD 70 %
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TECHLITE PEN NEEDLES 32G X 4 MM

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- TERUMO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- THERAGAUZE PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM
- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 31G X 8 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

- |   |   |
|---|---|
| • TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM       | • ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML        |
| • TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM       | • ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML          |
| • TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM       | • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML        |
| • TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM       | • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML        |
| • TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML    | • ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML          |
| • TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML      | • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML        |
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML    | • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML        |
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML    | • ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML          |
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML      | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML       |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML   | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC) |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML   | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)  |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML     | • ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML         |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML   | • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML        |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML   | • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML        |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML     | • ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML          |
| • TRUEPLUS PEN NEEDLES 29G X 12MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC) |
| • TRUEPLUS PEN NEEDLES 31G X 5 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX)  |
| • TRUEPLUS PEN NEEDLES 31G X 6 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC) |
| • TRUEPLUS PEN NEEDLES 31G X 8 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX)  |
| • TRUEPLUS PEN NEEDLES 32G X 4 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML         |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML | • ULTICARE MICRO PEN NEEDLES 32G X 4 MM             |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML   | • ULTICARE MINI PEN NEEDLES 30G X 5 MM              |

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

- ULTICARE MINI PEN NEEDLES 31G X 6 MM
- ULTICARE MINI PEN NEEDLES 32G X 6 MM
- ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)
- ULTICARE PEN NEEDLES 29G X 12.7MM (RX)
- ULTICARE PEN NEEDLES 31G X 5 MM
- ULTICARE SHORT PEN NEEDLES 30G X 8 MM
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)
- ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTILET INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTILET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTILET INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTILET INSULIN SYRINGE 31G X 1/4" 0.3 ML
- ULTILET INSULIN SYRINGE 31G X 1/4" 1 ML
- ULTILET INSULIN SYRINGE 31G X 15/64" 0.3 ML (OTC)
- ULTILET INSULIN SYRINGE 31G X 15/64" 0.3 ML (RX)
- ULTILET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- ULTILET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 1/2" 0.3 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 0.5 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 1 ML
- ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 0.5 ML
- ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 1 ML
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- |   |   |
|---|---|
| • ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM          | • ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML  |
| • ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM          | • ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML  |
| • ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML  | • ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML    |
| • ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML | • ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML |
| • ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML | • ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML   |
| • ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML       | • ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM        |
| • ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML       | • ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM       |
| • ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML         | • ULTRA-THIN II PEN NEEDLES 29G X 12.7MM          |
| • ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML       | • ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML     |
| • ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML       | • ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML       |
| • ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML         | • ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML    |
| • ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML      | • ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML    |
| • ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML      | • ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML      |
| • ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML        | • ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML    |
| • ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML      | • ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML    |
| • ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML      | • ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML      |
| • ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML        | • ULTRACARE PEN NEEDLES 31G X 5 MM                |
| • ULTRA THIN PEN NEEDLES 32G X 4 MM                 | • ULTRACARE PEN NEEDLES 31G X 6 MM                |
| • ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML   | • ULTRACARE PEN NEEDLES 31G X 8 MM                |
| • ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML    | • ULTRACARE PEN NEEDLES 32G X 4 MM                |
| • ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML    | • ULTRACARE PEN NEEDLES 32G X 5 MM                |
| • ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML      | • ULTRACARE PEN NEEDLES 32G X 6 MM                |

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM
- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML
- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD PAD 70 %

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	LIFETIME
<b>Other Criteria</b>	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

INTERFERON FOR MS-AVONEX

Products Affected

- AVONEX PEN INTRAMUSCULAR  
AUTO-INJECTOR KIT
- AVONEX PREFILLED  
INTRAMUSCULAR PREFILLED  
SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## INTERFERON FOR MS-BETASERON

### Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **INTERFERON FOR MS-PLEGRIDY**

### **Products Affected**

- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR
- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## INTERFERON GAMMA-1B

### Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IPILIMUMAB

## Products Affected

- YERVOY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO
<b>Other Criteria</b>	RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS). THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IVACAFTOR

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: LIFETIME
<b>Other Criteria</b>	CF: INITIAL: NOT HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE. RENEWAL: IMPROVEMENT IN CLINICAL STATUS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **IVOSIDENIB**

---

### **Products Affected**

- TIBSOVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# IXAZOMIB

## Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# LANREOTIDE

## Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT  
SUBCUTANEOUS SOLUTION 60  
MG/0.2ML, 90 MG/0.3ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	ACROMEGALY: INITIAL: 3 MOS, RENEWAL: 12 MOS.GEP-NETS, CARCINOID SYNDROME: 12 MOS.
Other Criteria	ACROMEGALY: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE GENERIC OCTREOTIDE INJECTION. RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LAPATINIB**

---

### **Products Affected**

- *lapatinib ditosylate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## LAROTRECTINIB

### Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LAZERTINIB**

---

### **Products Affected**

- LAZCLUZE ORAL TABLET 240 MG,  
80 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LEDIPASVIR-SOFOSBUVIR**

### **Products Affected**

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI. REQUESTS FOR HARVONI 45MG-200MG PELLETS: PATIENT IS UNABLE TO SWALLOW TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## LENALIDOMIDE

---

### Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# LENVATINIB

## Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# LETERMOVIR

## Products Affected

- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.
Other Criteria	HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## LEUPROLIDE

### Products Affected

- leuprolide acetate injection*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PROSTATE CANCER: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# LEUPROLIDE DEPOT

## Products Affected

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LEUPROLIDE-ELIGARD**

---

### **Products Affected**

- ELIGARD

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LEUPROLIDE-LUPRON DEPOT**

### **Products Affected**

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.
<b>Other Criteria</b>	INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LEUPROLIDE-LUPRON DEPOT-PED**

### **Products Affected**

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVELS OF FOLLICLE-STIMULATING HORMONE (FSH) GREATER THAN 4.0 MIU/ML AND LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVELS OF FSH GREATER THAN 5.0 MIU/ML AND LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# L-GLUTAMINE

## Products Affected

- *l-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: LIFETIME.
Other Criteria	SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## LIDOCAINE OINTMENT

### Products Affected

- *lidocaine external ointment 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LIDOCAINE PATCH**

### **Products Affected**

- *lidocaine external patch 5 %*
- *lidocan*
- ZTLIDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	1) PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA, 2) NEUROPATHY DUE TO DIABETES MELLITUS, 3) CHRONIC BACK PAIN, OR 4) OSTEOARTHRITIS OF THE KNEE OR HIP.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## LIDOCAINE PRILOCAINE

### Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## LONCASTUXIMAB TESIRINE-LPYL

---

### Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LORLATINIB**

---

### **Products Affected**

- LORBRENA ORAL TABLET 100 MG,  
25 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **LOTILANER**

---

### **Products Affected**

- XDEMVY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 WEEKS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## LUMACAFITOR-IVACAFITOR

### Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CYSTIC FIBROSIS (CF): CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CF.
Age Restrictions	
Prescriber Restrictions	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: LIFETIME.
Other Criteria	CF: RENEWAL: IMPROVEMENT IN CLINICAL STATUS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# MACITENTAN

## Products Affected

- OPSUMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## MARGETUXIMAB-CMKB

---

### Products Affected

- MARGENZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MARIBAVIR**

---

### **Products Affected**

- LIVTENCITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# MECASERMIN

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. RENEWAL: IMPROVEMENT WHILE ON THERAPY (I.E., INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MECHLORETHAMINE**

---

### **Products Affected**

- VALCHLOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MEPOLIZUMAB**

### **Products Affected**

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: ASTHMA: 12 MO. CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA: 12 MO.
<b>Other Criteria</b>	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MIDOSTAURIN**

---

### **Products Affected**

- RYDAPT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# MIFEPRISTONE

## Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (2 OR MORE TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (2 OR MORE TESTS TO CONFIRM).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICOIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE, ETC.), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MILTEFOSINE**

---

### **Products Affected**

- IMPAVIDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MIRDAMETINIB**

---

### **Products Affected**

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## MIRVETUXIMAB SORAVTANSINE-GYNX

### Products Affected

- ELAHERE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **MOMELOTINIB**

---

### **Products Affected**

- OJJAARA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## MOSUNETUZUMAB-AXGB

### Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NARCOLEPSY AGENTS**

### **Products Affected**

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NAXITAMAB-GQGK**

---

**Products Affected**

- DANYELZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NERATINIB**

### **Products Affected**

- NERLYNX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NILOTINIB**

---

### **Products Affected**

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND TASIGNA IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NILOTINIB-DANZITEN**

### **Products Affected**

- DANZITEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# NINTEDANIB

## Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) BASELINE FORCED VITAL CAPACITY (FVC) AT LEAST 50% OF PREDICTED VALUE. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 45% OF PREDICTED VALUE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.
<b>Other Criteria</b>	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ACTEMRA

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	SUBQ. PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENER/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# NIRAPARIB

## Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## NIRAPARIB-ABIRATERONE

### Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# **NIROGACESTAT**

---

**Products Affected**

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# NITISINONE

## Products Affected

- nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# NIVOLUMAB

## Products Affected

- OPDIVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NIVOLUMAB-HYALURONIDASE-NVHY**

### **Products Affected**

- OPDIVO QVANTIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **NIVOLUMAB-RELATLIMAB-RMBW**

---

**Products Affected**

- OPDUALAG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## NOGAPENDEKIN ALFA

---

### Products Affected

- ANKTIVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	40 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **OCRELIZUMAB**

---

**Products Affected**

- OCREVUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## OCRELIZUMAB-HYALURONIDASE-OCSQ

### Products Affected

- OCREVUS ZUNOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## OFATUMUMAB-SQ

---

### Products Affected

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **OLANZAPINE/SAMIDORPHAN**

### **Products Affected**

- LYBALVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	SCHIZOPHRENIA, BIPOLAR I: PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	SCHIZOPHRENIA: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF LURASIDONE OR ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE. BIPOLAR I: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# OLAPARIB

## Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **OLUTASIDENIB**

---

### **Products Affected**

- REZLIDHIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **OMACETAXINE**

---

### **Products Affected**

- SYNRIBO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# OMALIZUMAB

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) ALLERGEN SPECIFIC IGE SERUM LEVEL OF AT LEAST 6 KUA/L TO AT LEAST ONE FOOD, OR POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
<b>Other Criteria</b>	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED AGENT: NUCALA, DUPIXENT, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. FOOD ALLERGY: 1) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 2) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 3) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY.</p>

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **OSIMERTINIB**

---

### **Products Affected**

- TAGRISSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## OXANDROLONE

### Products Affected

- oxandrolone oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## PACRITINIB

### Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PALBOCICLIB**

### **Products Affected**

- IBRANCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ADVANCED OR METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE PREFERRED AGENTS, WHERE INDICATIONS ALIGN: KISQALI, VERZENIO.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## PARATHYROID HORMONE

### Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: 1) TRIAL OF OR CONTRAINDICATION TO CALCITRIOL, 2) HYPOPARATHYROIDISM IS NOT DUE TO A CALCIUM SENSING RECEPTOR (CSR) MUTATION, AND 3) HYPOPARATHYROIDISM IS NOT CONSIDERED ACUTE POST-SURGICAL HYPOPARATHYROIDISM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## PASIREOTIDE DIASPARTATE

### Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# PAZOPANIB

## Products Affected

- *pazopanib hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PEGFILGRASTIM - APGF**

---

### **Products Affected**

- NYVEPRIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PREScribed BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## PEGFILGRASTIM-NEULASTA ONPRO

### Products Affected

- NEULASTA ONPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PEGINTERFERON ALFA-2A**

### **Products Affected**

- PEGASYS SUBCUTANEOUS  
SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST).
<b>Coverage Duration</b>	HEP B/HEP C: 48 WEEKS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PEGVISOMANT**

---

### **Products Affected**

- SOMAVERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# PEMBROLIZUMAB

## Products Affected

- KEYTRUDA INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PEMIGATINIB**

---

**Products Affected**

- PEMAZYRE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PENICILLAMINE TABLET**

### **Products Affected**

- *penicillamine oral tablet*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PEXIDARTINIB**

---

### **Products Affected**

- TURALIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# **PIMAVANSERIN**

## **Products Affected**

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER
<b>Prescriber Restrictions</b>	PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST).
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PIRFENIDONE**

### **Products Affected**

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50% AT BASELINE.
<b>Age Restrictions</b>	IPF: INITIAL: 18 YEARS OR OLDER.
<b>Prescriber Restrictions</b>	IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## PIRTOBRUTINIB

### Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **POMALIDOMIDE**

---

### **Products Affected**

- POMALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PONATINIB**

---

**Products Affected**

- ICLUSIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## POSACONAZOLE TABLET

### Products Affected

- posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **PRALSETINIB**

---

### **Products Affected**

- GAVRETO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## PYRIMETHAMINE

### Products Affected

- pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.
Other Criteria	TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **QUININE**

---

### **Products Affected**

- *quinine sulfate oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## QUIZARTINIB

---

### Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **REGORAFENIB**

---

### **Products Affected**

- STIVARGA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RELUGOLIX**

---

### **Products Affected**

- ORGOVYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## REPOTRECTINIB

---

### Products Affected

- AUGTYRO ORAL CAPSULE 160 MG,  
40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RESLIZUMAB**

### **Products Affected**

- CINQAIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ASTHMA: INITIAL: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, 3) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: FASENRA, NUCALA, DUPIXENT, AND 4) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. RENEWAL: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## RETIFANLIMAB-DLWR

---

### Products Affected

- ZYNYZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **REVUMENIB**

---

### **Products Affected**

- REVUFORJ ORAL TABLET 110 MG,  
160 MG, 25 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# RIBOCICLIB

## Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RIBOCICLIB-LETROZOLE**

---

**Products Affected**

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RIFAXIMIN**

---

### **Products Affected**

- XIFAXAN ORAL TABLET 200 MG, 550 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.
<b>Other Criteria</b>	HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# RILONACEPT

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CAPS, DIRA: LIFETIME. RP: 12 MONTHS.
<b>Other Criteria</b>	<p>CAPS: NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS.</p> <p>DIRA: 1) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE</p>

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# RIMEGEPANT

## Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	<p>INITIAL: ACUTE MIGRAINE TREATMENT: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT.</p> <p>EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: ACUTE MIGRAINE TREATMENT: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.</p> <p>EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.</p>

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# RIOCIQUAT

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## RIPRETINIB

---

### Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RISANKIZUMAB-RZAA**

### **Products Affected**

- SKYRIZI
- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSO. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSO: 1)

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RITUXIMAB AND HYALURONIDASE HUMAN-SQ**

### **Products Affected**

- RITUXAN HYCELA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RITUXIMAB-ABBS**

### **Products Affected**

- TRUXIMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RITUXIMAB-ARRX**

### **Products Affected**

- RIABNI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS (RA): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RITUXIMAB-PVVR**

### **Products Affected**

- RUXIENCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## ROPEGINTERFERON ALFA-2B-NJFT

### Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **RUCAPARIB**

### **Products Affected**

- RUBRACA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# RUXOLITINIB

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.
Other Criteria	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

SAPROPTERIN

Products Affected

- javygtor oral tablet
- sapropterin dihydrochloride oral tablet

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.
Other Criteria	HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SECUKINUMAB IV**

### **Products Affected**

- COSENTYX INTRAVENOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. THIS DRUG

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SECUKINUMAB SQ**

### **Products Affected**

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSO. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. RENEWAL: PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. ERA, HS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## SELEXIPAG

### Products Affected

- UPTRAVI INTRAVENOUS
- UPTRAVI TITRATION
- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# SELINEXOR

## Products Affected

- XPOVIO (100 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 50  
MG
- XPOVIO (40 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 10  
MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (60 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 60  
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SELPERCATINIB**

---

### **Products Affected**

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SELUMETINIB**

---

### **Products Affected**

- KOSELUGO ORAL CAPSULE 10 MG,  
25 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SILDENAFIL TABLET**

### **Products Affected**

- sildenafil citrate oral tablet 20 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SIPONIMOD**

---

### **Products Affected**

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## SIROLIMUS PROTEIN-BOUND

---

### Products Affected

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

## SODIUM OXYBATE-XYREM

### Products Affected

- sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY, AND 3) AGES 7 TO 17 YEARS: TRIAL, FAILURE OF, OR CONTRAINDICATION TO ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SOFOSBUVIR/VELPATASVIR**

### **Products Affected**

- EPCLUSA ORAL PACKET 150-37.5      • EPCLUSA ORAL TABLET  
MG, 200-50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR**

### **Products Affected**

- VOSEVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

## **SOMATROPIN - NORDITROPIN**

### **Products Affected**

- NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.
<b>Required Medical Information</b>	INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), TURNER SYNDROME (TS), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ADULT GHD: GHD ALONE OR ASSOCIATED WITH MULTIPLE HORMONE DEFICIENCIES (HYPOPITUITARISM), AS A RESULT OF PITUITARY DISEASE, HYPOTHALAMIC DISEASE, SURGERY, RADIATION THERAPY, OR TRAUMA, OR FOR CONTINUATION OF THERAPY FROM CHILDHOOD ONSET GHD. PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. RENEWAL: PEDIATRIC GHD: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. ISS, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	THE WRIST AND HAND. PWS: IMPROVEMENT IN BODY COMPOSITION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SOMATROPIN - SEROSTIM**

### **Products Affected**

- SEROSTIM SUBCUTANEOUS  
SOLUTION RECONSTITUTED 4 MG, 5  
MG, 6 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
<b>Required Medical Information</b>	INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, 2) 7.5% UNINTENTIONAL WEIGHT LOSS OVER 6 MONTHS, 3) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 4) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 5) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 6) BMI LESS THAN 18.5 KG PER METER SQUARED.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 3 MONTHS.
<b>Other Criteria</b>	HIV/WASTING: INITIAL: 1) INADEQUATE RESPONSE TO ONE PREVIOUS THERAPY (E.G., MEGACE, APPETITE STIMULANTS, ANABOLIC STEROIDS). RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16  
Last Updated: 06/24/2025  
Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SONIDEGIB**

---

### **Products Affected**

- ODOMZO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SORAFENIB**

---

### **Products Affected**

- *sorafenib tosylate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SOTATERCEPT-CSRK**

### **Products Affected**

- WINREVAIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SOTORASIB**

---

### **Products Affected**

- LUMAKRAS ORAL TABLET 120 MG,  
240 MG, 320 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **STIRIPENTOL**

---

### **Products Affected**

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **SUNITINIB**

### **Products Affected**

- *sunitinib malate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB (GLEEVEC).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TADALAFIL - ADCIRCA, ALYQ**

### **Products Affected**

- *alyq*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TADALAFIL-CIALIS

### Products Affected

- tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# TALAZOPARIB

## Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TALQUETAMAB-TGVS

### Products Affected

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TARLATAMAB-DLLE

### Products Affected

- IMDELLTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

# TAZEMETOSTAT

## Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TEBENTAFUSP-TEBN

---

### Products Affected

- KIMMTRAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TECLISTAMAB-CQYV

---

### Products Affected

- TECVAYLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TELISOTUZUMAB VEDOTIN-TLLV

### Products Affected

- EMRELIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TELOTRISTAT

### Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TEPOTINIB**

---

### **Products Affected**

- TEPMETKO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TERIPARATIDE**

---

### **Products Affected**

- TERIPARATIDE SUBCUTANEOUS  
SOLUTION PEN-INJECTOR 620  
MCG/2.48ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# TESTOSTERONE

## Products Affected

- *testosterone gel 1.62 % transdermal*
- *testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# TESTOSTERONE CYPIONATE

## Products Affected

- *testosterone cypionate intramuscular  
solution 100 mg/ml, 200 mg/ml, 200 mg/ml  
(1 ml)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TESTOSTERONE ENANTHATE**

### **Products Affected**

- *testosterone enanthate intramuscular solution*
- XYOSTED

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.
<b>Other Criteria</b>	INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TETRABENAZINE

### Products Affected

- tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **THALIDOMIDE**

---

### **Products Affected**

- THALOMID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TISLELIZUMAB-JSGR

---

### Products Affected

- TEVIMBRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TISOTUMAB VEDOTIN-TFTV

### Products Affected

- TIVDAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TIVOZANIB**

---

### **Products Affected**

- FOTIVDA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TOCILIZUMAB IV**

### **Products Affected**

- ACTEMRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA.

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# TOCILIZUMAB SQ

## Products Affected

- ACTEMRA
- ACTEMRA ACTPEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS). RENEWAL: RA:

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. SSC-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TOCILIZUMAB-AAZG**

### **Products Affected**

- TYENNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA.

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TOCILIZUMAB-AAZG IV**

### **Products Affected**

- TYENNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PJIA, SJIA, GCA: 6 MOS. CRS: 1 MO. RENEWAL: RA, PJIA, SJIA, GCA: 12 MOS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. CYTOKINE RELEASE SYNDROME (CRS): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CRS. INITIAL/RENEWAL FOR PJIA, SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SAME INDICATION. RENEWAL FOR RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# TOFACITINIB

## Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PCJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PCJIA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PCJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PCJIA. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TOPICAL TRETINOIN

### Products Affected

- ALTRENO
- tretinoin external cream*

PA Criteria	Criteria Details
Exclusion Criteria	COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TORIPALIMAB-TPZI**

---

**Products Affected**

- LOQTORZI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME.
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# TOVORAFENIB

## Products Affected

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TRAMETINIB SOLUTION

### Products Affected

- MEKINIST ORAL SOLUTION  
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG): UNABLE TO SWALLOW MEKINIST TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TRAMETINIB TABLET

### Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TRASTUZUMAB-DKST

### Products Affected

- OGIVRI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TRASTUZUMAB-DTTB

---

### Products Affected

- ONTRUZANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TRASTUZUMAB-HYALURONIDASE-OYSK

### Products Affected

- HERCEPTIN HYLECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TRASTUZUMAB-PKRB**

---

### **Products Affected**

- HERZUMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TRASTUZUMAB-QYYP

### Products Affected

- TRAZIMERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TRAZODONE**

---

### **Products Affected**

- RALDESY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	MAJOR DEPRESSIVE DISORDER (MDD); CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TREMELIMUMAB-ACTL

### Products Affected

- IMJUDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.
Other Criteria	UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TRIENTINE CAPSULE

### Products Affected

- trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	WILSONS DISEASE: INITIAL: 1) LEIPZIG SCORE OF 4 OR GREATER, AND 2) TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## TRIFLURIDINE/TIPIRACIL

### Products Affected

- LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## TRIPTORELIN-TRELSTAR

### Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **TUCATINIB**

---

### **Products Affected**

- TUKYSA ORAL TABLET 150 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# UBROGEPANT

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **UPADACITINIB**

### **Products Affected**

- RINVOQ
- RINVOQ LQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). ATOPIC DERMATITIS (AD): ATOPIC DERMATITIS COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR ATOPIC DERMATITIS AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

PA Criteria	Criteria Details
	<p>BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR, AND 3) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITORS FOR ANY INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG), AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. GIANT CELL ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITOR FOR ANY INDICATION. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD.</p>
<b>Indications</b>	All FDA-approved Indications.

Formulary ID: 25262 version 16  
Last Updated: 06/24/2025  
Effective: 07/01/2025



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **USTEKINUMAB**

### **Products Affected**

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## USTEKINUMAB IV

### Products Affected

- STELARA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	2 MONTHS
Other Criteria	CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **USTEKINUMAB-AEKN IV**

### **Products Affected**

- SELARSDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **USTEKINUMAB-AEKN SQ**

### **Products Affected**

- SELARSDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **USTEKINUMAB-KFCE IV**

### **Products Affected**

- YESINTEK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **USTEKINUMAB-KFCE SQ**

### **Products Affected**

- YESINTEK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# VALBENAZINE

## Products Affected

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VANDETANIB**

---

### **Products Affected**

- CAPRELSA ORAL TABLET 100 MG,  
300 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## VANZACAFTOR-TEZACAFTOR-DEUTIVACAFTOR

### Products Affected

- ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
Other Criteria	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VEMURAFENIB**

---

**Products Affected**

- ZELBORAF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VENETOCLAX**

---

### **Products Affected**

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# VERICIGUAT

## Products Affected

- VERQUVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL:12 MONTHS.
<b>Other Criteria</b>	HEART FAILURE (HF): INITIAL: 1) NO CONCURRENT USE WITH LONG-ACTING NITRATES OR NITRIC OXIDE DONORS, RIOCIGUAT, OR PDE-5 INHIBITORS, 2) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED SGLT-2 INHIBITOR, AND 3) TRIAL OF OR CONTRAINDICATION TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (I.E., BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (I.E., SPIRONOLACTONE, EPLERENONE). RENEWAL: NO CONCURRENT USE WITH LONG-ACTING NITRATES OR NITRIC OXIDE DONORS, RIOCIGUAT, OR PDE-5 INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Formulary ID: 25262 version 16

Last Updated: 06/24/2025

Effective: 07/01/2025

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

# VIGABATRIN

## Products Affected

- *vigabatrin*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	REFRACTORY COMPLEX PARTIAL SEIZURES (CPS), INFANTILE SPASMS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CPS: TRIAL OF OR CONTRAINDICATION TO TWO ANTIEPILEPTIC AGENTS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VIMSELTINIB**

---

### **Products Affected**

- ROMVIMZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VISMODEGIB**

---

### **Products Affected**

- ERIVEDGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VORASIDENIB**

---

### **Products Affected**

- VORANIGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **VORICONAZOLE SUSPENSION**

### **Products Affected**

- *voriconazole oral suspension reconstituted*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.
<b>Other Criteria</b>	CANDIDA INFECTIONS: 1) TRIAL OF OR CONTRAINDICATION TO FLUCONAZOLE, AND 2) UNABLE TO SWALLOW TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## ZANIDATAMAB-HRII

---

### Products Affected

- ZIIHERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ZANUBRUTINIB**

---

### **Products Affected**

- BRUKINSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria

## ZENOCUTUZUMAB-ZBCO

---

### Products Affected

- BIZENGRI (750 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

## **ZOLBETUXIMAB-CLZB**

---

**Products Affected**

- VYLOY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP), Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO CSNP) 2025 Prior Authorization (PA) Criteria

## ZURANOLONE

---

### Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 DAYS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

**INDEX**

**A**

abiraterone acetate .....	7	ALECENSA.....	19
abirtega.....	7	ALTRENO.....	350
ABOUTTIME PEN NEEDLE 30G X 8 MM .....	155, 174	ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG.....	58
ABOUTTIME PEN NEEDLE 31G X 5 MM .....	155, 174	ALUNBRIG ORAL TABLET THERAPY PACK.....	58
ABOUTTIME PEN NEEDLE 31G X 8 MM .....	155, 174	ALVAIZ.....	103
ABOUTTIME PEN NEEDLE 32G X 4 MM .....	155, 174	ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG.....	383
ACTEMRA.....	340, 341, 342, 343	alyq.....	320
ACTEMRA ACTPEN .....	342, 343	ANKTIVA .....	233
ACTHAR.....	73	AQ INSULIN SYRINGE 31G X 5/16... 155, 174	
ACTHAR GEL SUBCUTANEOUS PEN- INJECTOR 40 UNIT/0.5ML, 80 UNIT/ML.....	73	AQINJECT PEN NEEDLE 31G X 5 MM .....	155, 174
ACTIMMUNE.....	178	AQINJECT PEN NEEDLE 32G X 4 MM .....	155, 174
ADEMPAS .....	284, 285	ARCALYST .....	280, 281
ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM.....	155, 174	ARIKAYCE.....	21
ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM.....	155, 174	armodafinil.....	219
ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM.....	155, 174	ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM.....	155, 174
ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM.....	155, 174	ASSURE ID INSULIN SAFETY SYR 29G X 1/2.....	155, 174
ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM.....	155, 174	ASSURE ID INSULIN SAFETY SYR 31G X 15/64.....	155, 174
ADVOCATE INSULIN SYRINGE 29G X 1/2 .....	155, 174	ASSURE ID PRO PEN NEEDLES 30G X 5 MM .....	155, 174
ADVOCATE INSULIN SYRINGE 30G X 5/16 .....	155, 174	AUGTYRO ORAL CAPSULE 160 MG, 40 MG .....	272
ADVOCATE INSULIN SYRINGE 31G X 5/16 .....	155, 174	AUM ALCOHOL PREP PADS PAD 70 % .....	155, 174
AIMOVIG.....	114	AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM.....	155, 174
AJOVY .....	130	AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM.....	155, 174
AKEEGA .....	227	AUM MINI INSULIN PEN NEEDLE 32G X 4 MM.....	155, 174
ALCOHOL PREP PAD.....	155, 174	AUM MINI INSULIN PEN NEEDLE 32G X 5 MM.....	155, 174
ALCOHOL PREP PAD 70 %.....	155, 174	AUM MINI INSULIN PEN NEEDLE 32G X 6 MM.....	155, 174
ALCOHOL PREP PADS PAD 70 % .... 155, 174		AUM MINI INSULIN PEN NEEDLE 32G X 8 MM.....	155, 174
ALCOHOL SWABS PAD.....	155, 174		
ALCOHOL SWABS PAD 70 % .... 155, 174			

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

AUM MINI INSULIN PEN NEEDLE 33G X 4 MM.....	155, 174	BD INSULIN SYRINGE 27.5G X 5/8..	156, 174
AUM MINI INSULIN PEN NEEDLE 33G X 5 MM.....	155, 174	BD INSULIN SYRINGE 27G X 1/2.....	156, 174
AUM MINI INSULIN PEN NEEDLE 33G X 6 MM.....	155, 174	BD INSULIN SYRINGE 29G X 1/2.....	156, 174
AUM PEN NEEDLE 32G X 4 MM	155, 174	BD INSULIN SYRINGE HALF-UNIT 31G X 5/16.....	156, 174
AUM PEN NEEDLE 32G X 5 MM	156, 174	BD INSULIN SYRINGE MICROFINE 27G X 5/8.....	156, 174
AUM PEN NEEDLE 32G X 6 MM	156, 174	BD INSULIN SYRINGE MICROFINE 28G X 1/2.....	156, 174
AUM PEN NEEDLE 33G X 4 MM	156, 174	BD INSULIN SYRINGE U-100 1 ML .	156, 174
AUM PEN NEEDLE 33G X 5 MM	156, 174	BD INSULIN SYRINGE U-500 ....	156, 174
AUM PEN NEEDLE 33G X 6 MM	156, 174	BD INSULIN SYRINGE ULTRAFINE 29G X 1/2.....	156, 174
AUM READYGARD DUO PEN NEEDLE 32G X 4 MM.....	156, 174	BD INSULIN SYRINGE ULTRAFINE 30G X 1/2.....	156, 174
AUM SAFETY PEN NEEDLE 31G X 4 MM .....	156, 174	BD INSULIN SYRINGE ULTRAFINE 31G X 5/16.....	156, 174
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG .....	87	BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM.....	156, 174
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG .....	87	BD PEN NEEDLE MINI U/F 31G X 5 MM .....	156, 174
AUSTEDO XR PATIENT TITRATION .	87	BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM.....	156, 174
AVMAPKI FAKZYNJA CO-PACK.....	37	BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM.....	156, 174
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT.....	175	BD PEN NEEDLE NANO U/F 32G X 4 MM .....	156, 174
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT.....	175	BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM.....	156, 174
AYVAKIT .....	36	BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM.....	156, 174
<b>B</b>		BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM.....	156, 174
BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG.....	113	BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2.....	156, 174
BD AUTOSHIELD 29G X 5MM...	156, 174	BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16.....	156, 174
BD AUTOSHIELD 29G X 8MM...	156, 174	BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64.....	156, 157, 174
BD AUTOSHIELD DUO 30G X 5 MM	156, 174	BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16.....	157, 174
BD ECLIPSE SYRINGE 30G X 1/2.....	156, 174		
BD INSULIN SYR ULTRAFINE II 31G X 5/16 .....	156, 174		
BD INSULIN SYRINGE 25G X 1.	156, 174		
BD INSULIN SYRINGE 25G X 5/8.....	156, 174		
BD INSULIN SYRINGE 26G X 1/2.....	156, 174		

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8.....	157, 174	CAREFINE PEN NEEDLES 31G X 8 MM .....	157, 174
BD SAFETY-LOK INSULIN SYRINGE 29G X 1/2.....	156, 174	CAREFINE PEN NEEDLES 32G X 4 MM .....	157, 174
BD SWAB SINGLE USE REGULAR PAD .....	157, 174	CAREFINE PEN NEEDLES 32G X 5 MM .....	157, 174
BD SWABS SINGLE USE BUTTERFLY PAD.....	157, 174	CAREFINE PEN NEEDLES 32G X 6 MM .....	157, 174
BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64.....	157, 174	CAREONE INSULIN SYRINGE 30G X 1/2 .....	157, 174
BD VEO INSULIN SYR ULTRAFINE 31G X 15/64.....	157, 174	CAREONE INSULIN SYRINGE 31G X 5/16 .....	157, 174
BD VEO INSULIN SYRINGE U/F 31G X 15/64 .....	157, 174	CARETOUCH ALCOHOL PREP PAD 70 % .....	157, 174
BENDAMUSTINE HCL INTRAVENOUS SOLUTION.....	46	CARETOUCH INSULIN SYRINGE 28G X 5/16 .....	157, 174
bendamustine hcl intravenous solution reconstituted.....	46	CARETOUCH INSULIN SYRINGE 29G X 5/16 .....	157, 174
BENDEKA .....	46	CARETOUCH INSULIN SYRINGE 30G X 5/16 .....	157, 174
BENLYSTA SUBCUTANEOUS.....	43	CARETOUCH INSULIN SYRINGE 31G X 5/16 .....	157, 174
BESREMI .....	293	CARETOUCH PEN NEEDLES 29G X 12MM .....	157, 174
betaine .....	49	CARETOUCH PEN NEEDLES 31G X 5 MM .....	157, 174
BETASERON SUBCUTANEOUS KIT	176	CARETOUCH PEN NEEDLES 31G X 6 MM .....	157, 174
bexarotene .....	53	CARETOUCH PEN NEEDLES 31G X 8 MM .....	157, 174
BIZENGRI (750 MG DOSE) .....	394	CARETOUCH PEN NEEDLES 32G X 4 MM .....	157, 174
bortezomib injection .....	55	CARETOUCH PEN NEEDLES 32G X 5 MM .....	157, 174
BORUZU .....	55	CARETOUCH PEN NEEDLES 33G X 4 MM .....	157, 174
bosentan .....	56	carglumic acid oral tablet soluble .....	65
BOSULIF ORAL CAPSULE 100 MG, 50 MG .....	57	CAYSTON.....	41
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....	57	CIMZIA (2 SYRINGE) .....	67, 68
BRAFTOVI ORAL CAPSULE 75 MG .	106	CIMZIA SUBCUTANEOUS KIT 2 X 200 MG .....	67, 68
BRUKINSA .....	393	CINQAIR.....	273, 274
<b>C</b>		CLEVER CHOICE COMFORT EZ 29G X 12MM .....	157, 174
CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG.....	61	CLEVER CHOICE COMFORT EZ 33G X 4 MM .....	157, 174
CALQUENCE .....	9		
CAPRELSA ORAL TABLET 100 MG, 300 MG .....	382		
CAREFINE PEN NEEDLES 29G X 12MM .....	157, 174		
CAREFINE PEN NEEDLES 30G X 8 MM .....	157, 174		
CAREFINE PEN NEEDLES 31G X 6 MM .....	157, 174		

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

CLICKFINE PEN NEEDLES 31G X 6 MM ..... 157, 174	COMFORT EZ PEN NEEDLES 33G X 6 MM ..... 158, 174
CLICKFINE PEN NEEDLES 31G X 8 MM ..... 158, 174	COMFORT EZ PEN NEEDLES 33G X 8 MM ..... 158, 174
CLICKFINE PEN NEEDLES 32G X 4 MM ..... 158, 174	COMFORT EZ PRO PEN NEEDLES 30G X 8 MM..... 158, 174
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG ..... 60	COMFORT EZ PRO PEN NEEDLES 31G X 4 MM..... 158, 174
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG ..... 60	COMFORT EZ PRO PEN NEEDLES 31G X 5 MM..... 158, 174
COMETRIQ (60 MG DAILY DOSE)..... 60	COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM..... 158, 174
COMFORT ASSIST INSULIN SYRINGE 29G X 1/2..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM..... 158, 174
COMFORT ASSIST INSULIN SYRINGE 31G X 5/16..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM..... 158, 174
COMFORT EZ INSULIN SYRINGE 28G X 1/2..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM..... 158, 174
COMFORT EZ INSULIN SYRINGE 29G X 1/2..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM..... 158, 174
COMFORT EZ INSULIN SYRINGE 30G X 1/2..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM..... 158, 174
COMFORT EZ INSULIN SYRINGE 30G X 5/16..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM..... 158, 174
COMFORT EZ INSULIN SYRINGE 31G X 15/64..... 158, 174	COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM..... 158, 174
COMFORT EZ INSULIN SYRINGE 31G X 5/16..... 158, 174	COPIKTRA..... 98
COMFORT EZ PEN NEEDLES 31G X 5 MM ..... 158, 174	CORTROPHIN ..... 73
COMFORT EZ PEN NEEDLES 31G X 6 MM ..... 158, 174	COSENTYX (300 MG DOSE)..... 299, 300
COMFORT EZ PEN NEEDLES 31G X 8 MM ..... 158, 174	COSENTYX INTRAVENOUS..... 297, 298
COMFORT EZ PEN NEEDLES 32G X 4 MM ..... 158, 174	COSENTYX SENSOREADY (300 MG) ..... 299, 300
COMFORT EZ PEN NEEDLES 32G X 5 MM ..... 158, 174	COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML ..... 299, 300
COMFORT EZ PEN NEEDLES 32G X 6 MM ..... 158, 174	COSENTYX UNOREADY ..... 299, 300
COMFORT EZ PEN NEEDLES 32G X 8 MM ..... 158, 174	COTELLIC ..... 72
COMFORT EZ PEN NEEDLES 33G X 4 MM ..... 158, 174	CURITY ALCOHOL PREPS PAD 70 % ..... 158, 174
COMFORT EZ PEN NEEDLES 33G X 5 MM ..... 158, 174	CURITY ALL PURPOSE SPONGES PAD 2..... 158, 174
	CURITY GAUZE PAD 2 ..... 159, 174
	CURITY GAUZE SPONGE PAD 2..... 159, 174
	CURITY SPONGES PAD 2..... 159, 174
	CVS GAUZE PAD 2 ..... 159, 174



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

CVS GAUZE STERILE PAD 2 ..... 159, 174  
CYLTEZO (2 PEN) ..... 16, 17  
CYLTEZO (2 SYRINGE) ..... 16, 17  
CYLTEZO-CD/UC/HS STARTER.... 16, 17  
CYLTEZO-PSORIASIS/UV STARTER 16,  
17

**D**

dalfampridine er ..... 79  
DANYELZA ..... 220  
DANZITEN ..... 223  
dasatinib oral tablet 100 mg, 140 mg, 20 mg,  
50 mg, 70 mg, 80 mg ..... 81  
DATROWAY ..... 82  
DAURISMO ORAL TABLET 100 MG, 25  
MG ..... 137  
deferasirox granules ..... 84, 85  
deferasirox oral tablet ..... 84, 85  
DERMACEA GAUZE SPONGE PAD 2  
..... 159, 174  
DERMACEA IV DRAIN SPONGES PAD  
2 ..... 159, 174  
DERMACEA NON-WOVEN SPONGES  
PAD 2 ..... 159, 174  
DERMACEA TYPE VII GAUZE PAD 2  
..... 159, 174  
DIACOMIT ORAL CAPSULE 250 MG,  
500 MG ..... 318  
DIACOMIT ORAL PACKET 250 MG, 500  
MG ..... 318  
DIATHRIVE PEN NEEDLE 31G X 5 MM  
..... 159, 174  
DIATHRIVE PEN NEEDLE 31G X 6 MM  
..... 159, 174  
DIATHRIVE PEN NEEDLE 31G X 8 MM  
..... 159, 174  
DIATHRIVE PEN NEEDLE 32G X 4 MM  
..... 159, 174  
diclofenac epolamine external ..... 89  
diclofenac sodium external solution 2 %.. 88  
dimethyl fumarate oral capsule delayed  
release 120 mg, 240 mg ..... 90  
dimethyl fumarate starter pack oral capsule  
delayed release therapy pack ..... 90  
dronabinol ..... 93  
DROPLET INSULIN SYRINGE 29G X 1/2  
..... 159, 174

DROPLET INSULIN SYRINGE 30G X 1/2  
..... 159, 174  
DROPLET INSULIN SYRINGE 30G X  
15/64 ..... 159, 174  
DROPLET INSULIN SYRINGE 30G X  
5/16 ..... 159, 174  
DROPLET INSULIN SYRINGE 31G X 1/4  
..... 159, 174  
DROPLET INSULIN SYRINGE 31G X  
15/64 ..... 159, 174  
DROPLET INSULIN SYRINGE 31G X  
5/16 ..... 159, 174  
DROPLET MICRON 34G X 3.5 MM... 159,  
174  
DROPLET PEN NEEDLES 29G X 10MM  
..... 159, 174  
DROPLET PEN NEEDLES 29G X 12MM  
..... 159, 174  
DROPLET PEN NEEDLES 30G X 8 MM  
..... 159, 174  
DROPLET PEN NEEDLES 31G X 5 MM  
..... 159, 174  
DROPLET PEN NEEDLES 31G X 6 MM  
..... 159, 174  
DROPLET PEN NEEDLES 31G X 8 MM  
..... 159, 174  
DROPLET PEN NEEDLES 32G X 4 MM  
..... 159, 174  
DROPLET PEN NEEDLES 32G X 5 MM  
..... 159, 174  
DROPLET PEN NEEDLES 32G X 6 MM  
..... 159, 174  
DROPLET PEN NEEDLES 32G X 8 MM  
..... 159, 174  
DROPSAFE ALCOHOL PREP PAD 70 %  
..... 159, 174  
DROPSAFE SAFETY PEN NEEDLES 31G  
X 5 MM..... 159, 174  
DROPSAFE SAFETY PEN NEEDLES 31G  
X 6 MM..... 159, 174  
DROPSAFE SAFETY PEN NEEDLES 31G  
X 8 MM..... 159, 174  
DROPSAFE SAFETY SYRINGE/NEEDLE  
29G X 1/2..... 159, 174  
DROPSAFE SAFETY SYRINGE/NEEDLE  
31G X 15/64..... 159, 160, 174

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

DROPSAFE SAFETY SYRINGE/NEEDLE  
31G X 5/16..... 160, 174  
droxidopa ..... 94  
DRUG MART ULTRA COMFORT SYR  
29G X 1/2..... 160, 174  
DRUG MART ULTRA COMFORT SYR  
30G X 5/16..... 160, 174  
DRUG MART UNIFINE PENTIPS 31G X  
5 MM ..... 160, 174  
DUPIXENT SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR .... 95, 97  
DUPIXENT SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE . 95,  
97

**E**

EASY COMFORT ALCOHOL PADS PAD  
..... 160, 174  
EASY COMFORT INSULIN SYRINGE  
29G X 5/16..... 160, 174  
EASY COMFORT INSULIN SYRINGE  
30G X 1/2..... 160, 174  
EASY COMFORT INSULIN SYRINGE  
30G X 5/16..... 160, 174  
EASY COMFORT INSULIN SYRINGE  
31G X 1/2..... 160, 174  
EASY COMFORT INSULIN SYRINGE  
31G X 5/16..... 160, 174  
EASY COMFORT INSULIN SYRINGE  
32G X 5/16..... 160, 174  
EASY COMFORT PEN NEEDLES 29G X  
4MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 29G X  
5MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 31G X  
5 MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 31G X  
6 MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 31G X  
8 MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 32G X  
4 MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 33G X  
4 MM ..... 160, 174  
EASY COMFORT PEN NEEDLES 33G X  
5 MM ..... 160, 174

EASY COMFORT PEN NEEDLES 33G X  
6 MM ..... 160, 174  
EASY GLIDE PEN NEEDLES 33G X 4  
MM ..... 160, 174  
EASY TOUCH ALCOHOL PREP  
MEDIUM PAD 70 %..... 160, 174  
EASY TOUCH FLIPLOCK INSULIN SY  
29G X 1/2..... 160, 174  
EASY TOUCH FLIPLOCK INSULIN SY  
30G X 1/2..... 160, 174  
EASY TOUCH FLIPLOCK INSULIN SY  
30G X 5/16..... 160, 174  
EASY TOUCH FLIPLOCK INSULIN SY  
31G X 5/16..... 160, 174  
EASY TOUCH FLIPLOCK SAFETY SYR  
27G X 1/2..... 160, 174  
EASY TOUCH INSULIN BARRELS U-  
100 1 ML..... 160, 174  
EASY TOUCH INSULIN SAFETY SYR  
29G X 1/2..... 160, 174  
EASY TOUCH INSULIN SAFETY SYR  
30G X 1/2..... 160, 174  
EASY TOUCH INSULIN SAFETY SYR  
30G X 5/16..... 160, 174  
EASY TOUCH INSULIN SYRINGE 27G  
X 1/2..... 161, 174  
EASY TOUCH INSULIN SYRINGE 27G  
X 5/8..... 161, 174  
EASY TOUCH INSULIN SYRINGE 28G  
X 1/2..... 161, 174  
EASY TOUCH INSULIN SYRINGE 29G  
X 1/2..... 161, 174  
EASY TOUCH INSULIN SYRINGE 30G  
X 1/2..... 161, 174  
EASY TOUCH INSULIN SYRINGE 30G  
X 5/16..... 161, 174  
EASY TOUCH INSULIN SYRINGE 31G  
X 5/16..... 161, 174  
EASY TOUCH PEN NEEDLES 29G X  
12MM ..... 161, 174  
EASY TOUCH PEN NEEDLES 30G X 5  
MM ..... 161, 174  
EASY TOUCH PEN NEEDLES 30G X 6  
MM ..... 161, 174  
EASY TOUCH PEN NEEDLES 30G X 8  
MM ..... 161, 174

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

EASY TOUCH PEN NEEDLES 31G X 5 MM .....	161, 174	EMBECTA INSULIN SYRINGE U-100 28G X 1/2.....	161, 174
EASY TOUCH PEN NEEDLES 31G X 6 MM .....	161, 174	EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM.....	162, 174
EASY TOUCH PEN NEEDLES 31G X 8 MM .....	161, 174	EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM.....	162, 174
EASY TOUCH PEN NEEDLES 32G X 4 MM .....	161, 174	EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM.....	162, 174
EASY TOUCH PEN NEEDLES 32G X 5 MM .....	161, 174	EMBRACE PEN NEEDLES 29G X 12MM .....	162, 174
EASY TOUCH PEN NEEDLES 32G X 6 MM .....	161, 174	EMBRACE PEN NEEDLES 30G X 5 MM .....	162, 174
EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM.....	161, 174	EMBRACE PEN NEEDLES 30G X 8 MM .....	162, 174
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM.....	161, 174	EMBRACE PEN NEEDLES 31G X 5 MM .....	162, 174
EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM.....	161, 174	EMBRACE PEN NEEDLES 31G X 6 MM .....	162, 174
EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2.....	161, 174	EMBRACE PEN NEEDLES 31G X 8 MM .....	162, 174
EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2.....	161, 174	EMBRACE PEN NEEDLES 32G X 4 MM .....	162, 174
EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16.....	161, 174	EMGALITY .....	133
EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16.....	161, 174	EMGALITY (300 MG DOSE) .....	133
ELAHERE .....	216	EMRELIS .....	328
ELIGARD .....	193	ENBREL MINI.....	117, 118
ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML .....	102	ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML .....	117, 118
EMBECTA AUTOSHIELD DUO 30G X 5 MM .....	161, 174	ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	117, 118
EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64 .....	161, 174	ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED.....	117, 118
EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16 .....	161, 174	ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR	117, 118
EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2.....	161, 174	EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG.....	309
EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16.....	161, 174	EPCLUSA ORAL TABLET.....	309
EMBECTA INSULIN SYRINGE 28G X 1/2 .....	161, 174	EPIDIOLEX.....	62
EMBECTA INSULIN SYRINGE U-100 27G X 5/8.....	161, 174	EPKINLY .....	110
		EQL ALCOHOL SWABS PAD 70 %... 162, 174	
		EQL GAUZE PAD 2 .....	162, 174
		EQL INSULIN SYRINGE 30G X 5/16. 162, 174	
		ERBITUX .....	69
		ERIVEDGE.....	389

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

ERLEADA ORAL TABLET 240 MG, 60  
MG ..... 25  
erlotinib hcl oral tablet 100 mg, 150 mg, 25  
mg ..... 115  
everolimus oral tablet 10 mg, 2.5 mg, 5 mg,  
7.5 mg ..... 119  
everolimus oral tablet soluble ..... 120  
EXEL COMFORT POINT PEN NEEDLE  
29G X 12MM..... 162, 174  
**F**  
FASENRA ..... 47, 48  
FASENRA PEN..... 47, 48  
fentanyl citrate buccal lozenge on a handle  
..... 124  
FIFTY50 PEN NEEDLES 32G X 6 MM  
..... 162, 174  
fingolimod hcl ..... 128  
FINTEPLA..... 123  
FOTIVDA ..... 339  
FREESTYLE PRECISION INS SYR 30G X  
5/16 ..... 162, 174  
FREESTYLE PRECISION INS SYR 31G X  
5/16 ..... 162, 174  
FRUZAQLA ORAL CAPSULE 1 MG, 5  
MG ..... 131  
FYARRO ..... 307  
**G**  
GAUZE PADS PAD 2..... 162, 174  
GAUZE TYPE VII MEDI-PAK PAD 2 162,  
174  
GAVRETO ..... 266  
gefitinib ..... 135  
GILOTRIF ..... 18  
glatiramer acetate subcutaneous solution  
prefilled syringe 20 mg/ml, 40 mg/ml 138  
glatopa subcutaneous solution prefilled  
syringe 20 mg/ml, 40 mg/ml ..... 138  
GLOBAL ALCOHOL PREP EASE162, 174  
GLOBAL EASE INJECT PEN NEEDLES  
29G X 12MM..... 162, 174  
GLOBAL EASE INJECT PEN NEEDLES  
31G X 5 MM..... 162, 174  
GLOBAL EASE INJECT PEN NEEDLES  
31G X 8 MM..... 162, 174  
GLOBAL EASE INJECT PEN NEEDLES  
32G X 4 MM..... 162, 174

GLOBAL EASY GLIDE INSULIN SYR  
31G X 15/64..... 162, 174  
GLOBAL INJECT EASE INSULIN SYR  
28G X 1/2..... 162, 174  
GLOBAL INJECT EASE INSULIN SYR  
29G X 1/2..... 162, 174  
GLOBAL INJECT EASE INSULIN SYR  
30G X 1/2..... 162, 174  
GLOBAL INJECT EASE INSULIN SYR  
30G X 5/16..... 162, 174  
GLUCOPRO INSULIN SYRINGE 30G X  
1/2 ..... 162, 174  
GLUCOPRO INSULIN SYRINGE 30G X  
5/16 ..... 162, 174  
GLUCOPRO INSULIN SYRINGE 31G X  
5/16 ..... 162, 174  
GNP ALCOHOL SWABS PAD..... 162, 174  
GNP INSULIN SYRINGE 28G X 1/2 .. 163,  
174  
GNP INSULIN SYRINGE 29G X 1/2 .. 163,  
174  
GNP INSULIN SYRINGE 30G X 5/16 163,  
174  
GNP INSULIN SYRINGES 29GX1/2 .. 163,  
174  
GNP INSULIN SYRINGES 30G X 5/16  
..... 163, 174  
GNP INSULIN SYRINGES 30GX5/16 163,  
174  
GNP INSULIN SYRINGES 31GX5/16 163,  
174  
GNP STERILE GAUZE PAD 2..... 163, 174  
GNP ULTRA COM INSULIN SYRINGE  
30G X 5/16..... 163, 174  
GOMEKLI ORAL CAPSULE 1 MG, 2 MG  
..... 215  
GOMEKLI ORAL TABLET SOLUBLE215  
GOODSENSE ALCOHOL SWABS PAD  
70 % ..... 163, 174  
**H**  
HAEGARDA SUBCUTANEOUS  
SOLUTION RECONSTITUTED 2000  
UNIT, 3000 UNIT ..... 59  
HARVONI ORAL PACKET 33.75-150  
MG, 45-200 MG ..... 187  
HARVONI ORAL TABLET ..... 187

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16.....	163, 174	HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML .....	11, 13
HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16.....	163, 174	HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	11, 13
HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM.....	163, 174	HUMIRA-PED<40KG CROHNS STARTER.....	11, 13
HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM.....	163, 174	HUMIRA-PED>/=40KG CROHNS START .....	11, 13
HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM.....	163, 174	HUMIRA-PED>/=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	11, 13
HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM.....	163, 174	HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	11, 13
HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM.....	163, 174	HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	11, 13
HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM.....	163, 174		
HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM.....	163, 174		
HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM.....	163, 174		
H-E-B INCONTROL ALCOHOL PAD 163, 174		<b>I</b>	
H-E-B INCONTROL PEN NEEDLES 29G X 12MM.....	163, 174	IBRANCE .....	247
H-E-B INCONTROL PEN NEEDLES 31G X 5 MM.....	163, 174	icatibant acetate.....	147
H-E-B INCONTROL PEN NEEDLES 31G X 6 MM.....	163, 174	ICLUSIG.....	264
H-E-B INCONTROL PEN NEEDLES 31G X 8 MM.....	163, 174	IDHIFA .....	105
H-E-B INCONTROL PEN NEEDLES 32G X 4 MM.....	163, 174	imatinib mesylate oral tablet 100 mg, 400 mg .....	149
HERCEPTIN HYLECTA.....	357	IMBRUVICA ORAL CAPSULE 140 MG, 70 MG .....	146
HERZUMA.....	358	IMBRUVICA ORAL SUSPENSION....	146
HM STERILE ALCOHOL PREP PAD 163, 174		IMBRUVICA ORAL TABLET .....	146
HM STERILE PADS PAD 2.....	163, 174	IMDELLTRA .....	324
HM ULTICARE INSULIN SYRINGE 30G X 1/2.....	163, 174	IMJUDO .....	361
HM ULTICARE INSULIN SYRINGE 31G X 5/16.....	163, 174	IMKELDI.....	150
HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM.....	163, 174	IMPAVIDO.....	214
HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT.....	11, 13	INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM.....	163, 174
		INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM.....	163, 174
		INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM.....	163, 174
		INCRELEX.....	208
		infliximab.....	153, 154
		INGREZZA ORAL CAPSULE.....	381

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

INGREZZA ORAL CAPSULE SPRINKLE .....	381	IWILFIN .....	99
INGREZZA ORAL CAPSULE THERAPY PACK.....	381	<b>J</b>	
INLYTA ORAL TABLET 1 MG, 5 MG..	39	J & J GAUZE PAD 2.....	164, 174
INQOVI .....	83	JAKAFI.....	295
INREBIC.....	122	javygtor oral tablet .....	296
INSULIN SYRINGE 29G X 1/2 ....	163, 174	JAYPIRCA ORAL TABLET 100 MG, 50	
INSULIN SYRINGE 30G X 5/16 ..	163, 174	MG .....	262
INSULIN SYRINGE 31G X 5/16 ..	163, 174	JEMPERLI.....	92
INSULIN SYRINGE/NEEDLE 27G X 1/2 .....	164, 174	<b>K</b>	
INSULIN SYRINGE/NEEDLE 28G X 1/2 .....	164, 174	KALYDECO.....	180
INSULIN SYRINGE-NEEDLE U-100 27G X 1/2.....	163, 174	KENDALL HYDROPHILIC FOAM	
INSULIN SYRINGE-NEEDLE U-100 28G X 1/2.....	164, 174	DRESS PAD 2 .....	164, 174
INSULIN SYRINGE-NEEDLE U-100 30G X 5/16.....	164, 174	KENDALL HYDROPHILIC FOAM PLUS	
INSULIN SYRINGE-NEEDLE U-100 31G X 1/4.....	164, 174	PAD 2.....	164, 174
INSULIN SYRINGE-NEEDLE U-100 31G X 5/16.....	164, 174	KERENDIA .....	127
INSUPEN PEN NEEDLES 31G X 5 MM .....	164, 174	KESIMPTA.....	236
INSUPEN PEN NEEDLES 31G X 8 MM .....	164, 174	KEYTRUDA INTRAVENOUS	
INSUPEN PEN NEEDLES 32G X 4 MM .....	164, 174	SOLUTION.....	255
INSUPEN PEN NEEDLES 33G X 4 MM .....	164, 174	KIMMTRAK .....	326
INSUPEN SENSITIVE 32G X 6 MM ..	164, 174	KINERET SUBCUTANEOUS SOLUTION	
INSUPEN SENSITIVE 32G X 8 MM ..	164, 174	PREFILLED SYRINGE .....	23, 24
INSUPEN ULTRAFIN 29G X 12MM..	164, 174	KINRAY INSULIN SYRINGE 29G X 1/2 .....	164, 174
INSUPEN ULTRAFIN 30G X 8 MM...	164, 174	KISQALI (200 MG DOSE).....	277
INSUPEN ULTRAFIN 31G X 6 MM...	164, 174	KISQALI (400 MG DOSE).....	277
INSUPEN ULTRAFIN 31G X 8 MM...	164, 174	KISQALI (600 MG DOSE).....	277
ITOVEBI ORAL TABLET 3 MG, 9 MG .....	152	KISQALI FEMARA (200 MG DOSE) ..	278
		KISQALI FEMARA (400 MG DOSE) ..	278
		KISQALI FEMARA (600 MG DOSE) ..	278
		KMART VALU INSULIN SYRINGE 29G U-100 1 ML .....	164, 174
		KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML .....	164, 174
		KMART VALU INSULIN SYRINGE 30G U-100 1 ML .....	164, 174
		KOSELUGO ORAL CAPSULE 10 MG, 25 MG .....	304
		KRAZATI.....	10
		KROGER PEN NEEDLES 29G X 12MM .....	164, 174
		KROGER PEN NEEDLES 31G X 8 MM .....	164, 174
		KYNMOBI .....	27
		KYNMOBI TITRATION KIT .....	27
		<b>L</b>	
		LANREOTIDE ACETATE .....	183

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

lapatinib ditosylate .....	184	LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG.....	363
LAZCLUZE ORAL TABLET 240 MG, 80 MG .....	186	LOQTORZI.....	351
LEADER UNIFINE PENTIPS 31G X 5 MM .....	164, 174	LORBRENA ORAL TABLET 100 MG, 25 MG .....	202
LEADER UNIFINE PENTIPS 32G X 4 MM .....	164, 174	LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG.....	317
LEADER UNIFINE PENTIPS PLUS 31G X 5 MM.....	164, 174	LUNSUMIO .....	218
LEADER UNIFINE PENTIPS PLUS 31G X 8 MM.....	164, 174	LUPRON DEPOT (1-MONTH) .....	194, 195
lenalidomide.....	188	LUPRON DEPOT (3-MONTH) .....	194, 195
LENVIMA (10 MG DAILY DOSE) .....	189	LUPRON DEPOT (4-MONTH) .....	194, 195
LENVIMA (12 MG DAILY DOSE) .....	189	LUPRON DEPOT (6-MONTH) .....	194, 195
LENVIMA (14 MG DAILY DOSE) .....	189	LUPRON DEPOT-PED (3-MONTH) ....	196
LENVIMA (18 MG DAILY DOSE) .....	189	LUPRON DEPOT-PED (6-MONTH) ....	196
LENVIMA (20 MG DAILY DOSE) .....	189	LUTRATE DEPOT .....	192
LENVIMA (24 MG DAILY DOSE) .....	189	LYBALVI.....	237
LENVIMA (4 MG DAILY DOSE) .....	189	LYNPARZA ORAL TABLET .....	238
LENVIMA (8 MG DAILY DOSE) .....	189	LYTGOBI (12 MG DAILY DOSE) .....	132
LEUPROLIDE ACETATE (3 MONTH) 192		LYTGOBI (16 MG DAILY DOSE) .....	132
leuprolide acetate injection .....	191	LYTGOBI (20 MG DAILY DOSE) .....	132
l-glutamine oral packet .....	197	<b>M</b>	
lidocaine external ointment 5 % .....	198	MAGELLAN INSULIN SAFETY SYR 29G X 1/2.....	164, 165, 174
lidocaine external patch 5 % .....	199	MAGELLAN INSULIN SAFETY SYR 30G X 5/16.....	165, 174
lidocaine-prilocaine external cream.....	200	MARGENZA.....	206
lidocan.....	199	MAVENCLAD (10 TABS) .....	70
LITETOUCH INSULIN SYRINGE 28G X 1/2 .....	164, 174	MAVENCLAD (4 TABS) .....	70
LITETOUCH INSULIN SYRINGE 29G X 1/2 .....	164, 174	MAVENCLAD (5 TABS) .....	70
LITETOUCH INSULIN SYRINGE 30G X 5/16 .....	164, 174	MAVENCLAD (6 TABS) .....	70
LITETOUCH INSULIN SYRINGE 31G X 5/16 .....	164, 174	MAVENCLAD (7 TABS) .....	70
LITETOUCH PEN NEEDLES 29G X 12.7MM .....	164, 174	MAVENCLAD (8 TABS) .....	70
LITETOUCH PEN NEEDLES 31G X 5 MM .....	164, 174	MAVENCLAD (9 TABS) .....	70
LITETOUCH PEN NEEDLES 31G X 6 MM .....	164, 174	MAXICOMFORT II PEN NEEDLE 31G X 6 MM .....	165, 174
LITETOUCH PEN NEEDLES 31G X 8 MM .....	164, 174	MAXI-COMFORT INSULIN SYRINGE 28G X 1/2.....	165, 174
LITETOUCH PEN NEEDLES 32G X 4 MM .....	164, 174	MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM.....	165, 174
LIVTENCITY.....	207	MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM.....	165, 174
		MAXICOMFORT SYR 27G X 1/2 .....	165, 174
		MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG.....	306
		MAYZENT STARTER PACK.....	306

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

MEDIC INSULIN SYRINGE 30G X 5/16 ..... 165, 174	MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2 ..... 165, 174
MEDICINE SHOPPE PEN NEEDLES 29G X 12MM..... 165, 174	MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2 ..... 165, 174
MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM..... 165, 174	MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16 ..... 165, 174
MEDPURA ALCOHOL PADS 70 % EXTERNAL ..... 165, 174	morphine sulfate (concentrate) oral solution 100 mg/5ml ..... 145
MEIJER ALCOHOL SWABS PAD 70 % ..... 165, 174	MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR ..... 141
MEIJER PEN NEEDLES 29G X 12MM ..... 165, 174	MVASI..... 51
MEIJER PEN NEEDLES 31G X 6 MM 165, 174	<b>N</b>
MEIJER PEN NEEDLES 31G X 8 MM 165, 174	NATPARA..... 248
MEKINIST ORAL SOLUTION RECONSTITUTED..... 353	NERLYNX ..... 221
MEKINIST ORAL TABLET 0.5 MG, 2 MG ..... 354	NEULASTA ONPRO..... 252
MEKTOVI ..... 54	NIKTIMVO ..... 38
MICRODOT PEN NEEDLE 31G X 6 MM ..... 165, 174	NINLARO..... 182
MICRODOT PEN NEEDLE 32G X 4 MM ..... 165, 174	nitisinone..... 229
MICRODOT PEN NEEDLE 33G X 4 MM ..... 165, 174	NIVESTYM..... 126
mifepristone oral tablet 300 mg ..... 213	NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN- INJECTOR..... 311, 312
MIPLYFFA..... 30	NOVOFINE AUTOCOVER 30G X 8 MM ..... 165, 174
MIRASORB SPONGES 2..... 165, 174	NOVOFINE PEN NEEDLE 32G X 6 MM ..... 165, 174
MM PEN NEEDLES 32G X 4 MM 165, 174	NOVOFINE PLUS PEN NEEDLE 32G X 4 MM ..... 166, 174
modafinil oral tablet 100 mg, 200 mg..... 219	NOVOTWIST PEN NEEDLE 32G X 5 MM ..... 166, 174
MONOJECT INSULIN SYRINGE 25G X 5/8 ..... 165, 174	NUBEQA ..... 80
MONOJECT INSULIN SYRINGE 27G X 1/2 ..... 165, 174	NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR ..... 210, 211
MONOJECT INSULIN SYRINGE 28G X 1/2 ..... 165, 174	NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML ..... 210, 211
MONOJECT INSULIN SYRINGE 29G X 1/2 ..... 165, 174	NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED..... 210, 211
MONOJECT INSULIN SYRINGE 30G X 5/16 ..... 165, 174	NUPLAZID ORAL CAPSULE..... 260
MONOJECT INSULIN SYRINGE 31G X 5/16 ..... 165, 174	NUPLAZID ORAL TABLET 10 MG.... 260
MONOJECT INSULIN SYRINGE U-100 1 ML..... 165, 174	NURTEC..... 282, 283
	NYVEPRIA ..... 251
	<b>O</b>
	OCREVUS..... 234
	OCREVUS ZUNOVO ..... 235
	ODOMZO ..... 314



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

OFEV .....	224, 225	PEN NEEDLES 30G X 5 MM (OTC)...	166, 174
OGIVRI.....	355	PEN NEEDLES 30G X 8 MM .....	166, 174
OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG.....	228	PEN NEEDLES 32G X 4 MM (OTC)...	166, 174
OJEMDA ORAL SUSPENSION RECONSTITUTED.....	352	PEN NEEDLES 32G X 5 MM .....	166, 174
OJEMDA ORAL TABLET .....	352	penicillamine oral tablet.....	257, 258
OJJAARA .....	217	PENTIPS 29G X 12MM (RX).....	166, 174
ONAPGO.....	26	PENTIPS 31G X 5 MM (RX).....	166, 174
ONTRUZANT .....	356	PENTIPS 31G X 8 MM (RX).....	166, 174
ONUREG.....	40	PENTIPS 32G X 4 MM (RX).....	166, 174
OPDIVO .....	230	PENTIPS GENERIC PEN NEEDLES 29G X 12MM.....	166, 174
OPDIVO QVANTIG .....	231	PENTIPS GENERIC PEN NEEDLES 31G X 6 MM.....	166, 174
OPDUALAG.....	232	PENTIPS GENERIC PEN NEEDLES 32G X 6 MM.....	166, 174
OPSUMIT .....	205	PIP PEN NEEDLES 31G X 5MM 31G X 5 MM .....	166, 174
ORENCIA CLICKJECT.....	4, 5	PIP PEN NEEDLES 32G X 4MM 32G X 4 MM .....	166, 174
ORENCIA INTRAVENOUS .....	2, 3	PIQRAY (200 MG DAILY DOSE).....	20
ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	4, 5	PIQRAY (250 MG DAILY DOSE).....	20
ORFADIN ORAL SUSPENSION.....	229	PIQRAY (300 MG DAILY DOSE).....	20
ORGOVYX.....	271	pirfenidone oral capsule.....	261
ORLISSA ORAL TABLET 150 MG, 200 MG .....	101	pirfenidone oral tablet 267 mg, 534 mg, 801 mg .....	261
ORKAMBI ORAL TABLET .....	204	PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO- INJECTOR.....	177
ORSERDU ORAL TABLET 345 MG, 86 MG .....	100	PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	177
OTEZLA.....	28, 29	PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	177
oxandrolone oral .....	245	PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	177
OZEMPIC (0.25 OR 0.5 MG/DOSE).....	140	POMALYST .....	263
OZEMPIC (1 MG/DOSE) .....	140	posaconazole oral tablet delayed release	265
OZEMPIC (2 MG/DOSE) .....	140	PRECISION SUREDOSE PLUS SYR 29G X 1/2.....	166, 174
<b>P</b>		PRECISION SURE-DOSE SYRINGE 28G X 1/2.....	166, 174
pazopanib hcl .....	250	PRECISION SURE-DOSE SYRINGE 29G X 1/2.....	166, 174
PC UNIFINE PENTIPS 31G X 5 MM..	166, 174		
PC UNIFINE PENTIPS 31G X 6 MM..	166, 174		
PC UNIFINE PENTIPS 31G X 8 MM..	166, 174		
PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML .....	253		
PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	253		
PEMAZYRE .....	256		
PEN NEEDLE/5-BEVEL TIP 32G X 4 MM .....	166, 174		

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

PRECISION SURE-DOSE SYRINGE 30G X 3/8.....	166, 174	PURE COMFORT PEN NEEDLE 32G X 5 MM .....	166, 174
PRECISION SURE-DOSE SYRINGE 30G X 5/16.....	166, 174	PURE COMFORT PEN NEEDLE 32G X 6 MM .....	166, 174
PREFERRED PLUS INSULIN SYRINGE 28G X 1/2.....	166, 174	PURE COMFORT PEN NEEDLE 32G X 8 MM .....	166, 174
PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM.....	166, 174	PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM.....	167, 174
PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM.....	166, 174	PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM.....	167, 174
PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM.....	166, 174	PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM.....	167, 174
PREVENT SAFETY PEN NEEDLES 31G X 6 MM.....	166, 174	PX SHORTLENGTH PEN NEEDLES 31G X 8 MM.....	167, 174
PREVENT SAFETY PEN NEEDLES 31G X 8 MM.....	166, 174	pyrimethamine oral .....	267
PREVYMIS ORAL TABLET .....	190	<b>Q</b>	
PRO COMFORT ALCOHOL PAD 70 % .....	166, 174	QC ALCOHOL .....	167, 174
PRO COMFORT INSULIN SYRINGE 30G X 1/2.....	166, 174	QC ALCOHOL SWABS PAD 70 %.....	167, 174
PRO COMFORT INSULIN SYRINGE 30G X 5/16.....	166, 174	QC BORDER ISLAND GAUZE PAD 2 .....	167, 174
PRO COMFORT INSULIN SYRINGE 31G X 5/16.....	166, 174	QINLOCK.....	286
PRO COMFORT PEN NEEDLES 31G X 8 MM .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM.....	167, 174
PRO COMFORT PEN NEEDLES 32G X 4 MM .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM.....	167, 174
PRO COMFORT PEN NEEDLES 32G X 5 MM .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM.....	167, 174
PRO COMFORT PEN NEEDLES 32G X 6 MM .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM.....	167, 174
PRODIGY INSULIN SYRINGE 28G X 1/2 .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM.....	167, 174
PRODIGY INSULIN SYRINGE 31G X 5/16 .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM.....	167, 174
PROMACTA ORAL PACKET 12.5 MG, 25 MG .....	104	QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM.....	167, 174
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG .....	104	QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM.....	167, 174
PURE COMFORT ALCOHOL PREP PAD .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM.....	167, 174
PURE COMFORT PEN NEEDLE 32G X 4 MM .....	166, 174	QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM.....	167, 174
		quinine sulfate oral.....	268
		QULIPTA .....	34

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

<b>R</b>	
RA ALCOHOL SWABS PAD 70 %.....	167, 174
RA INSULIN SYRINGE 29G X 1/2.....	167, 174
RA INSULIN SYRINGE 30G X 5/16...	167, 174
ra isopropyl alcohol wipes .....	167, 174
RA PEN NEEDLES 31G X 5 MM.	167, 174
RA PEN NEEDLES 31G X 8 MM.	167, 174
RA STERILE PAD 2 .....	167, 174
RALDESY .....	360
RAYA SURE PEN NEEDLE 29G X 12MM .....	167, 174
RAYA SURE PEN NEEDLE 31G X 4 MM .....	167, 174
RAYA SURE PEN NEEDLE 31G X 5 MM .....	167, 174
RAYA SURE PEN NEEDLE 31G X 6 MM .....	167, 174
REALITY INSULIN SYRINGE 28G X 1/2 .....	167, 174
REALITY INSULIN SYRINGE 29G X 1/2 .....	167, 174
REALITY SWABS PAD.....	167, 174
RELION ALCOHOL SWABS PAD .....	167, 174
RELI-ON INSULIN SYRINGE 29G 0.3 ML.....	167, 174
RELI-ON INSULIN SYRINGE 29G 0.5 ML.....	167, 174
RELI-ON INSULIN SYRINGE 29G X 1/2 .....	167, 174
RELION INSULIN SYRINGE 31G X 15/64 .....	167, 174
RELION MINI PEN NEEDLES 31G X 6 MM .....	167, 174
RELION PEN NEEDLES 31G X 6 MM	167, 174
RELION PEN NEEDLES 31G X 8 MM	167, 174
RESTORE CONTACT LAYER PAD 2	167, 174
RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000	
	UNIT/ML, 3000 UNIT/ML, 4000
	UNIT/ML, 40000 UNIT/ML ..... 111, 112
	RETEVMO ORAL CAPSULE 40 MG, 80 MG ..... 303
	RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG ..... 303
	REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG..... 276
	REZLIDHIA ..... 239
	REZUROCK ..... 44
	RIABNI..... 291
	RINVOQ ..... 367, 368, 369
	RINVOQ LQ..... 367, 368, 369
	RITUXAN HYCELA ..... 289
	ROMVIMZA ..... 388
	ROZLYTREK ORAL CAPSULE 100 MG, 200 MG ..... 107
	ROZLYTREK ORAL PACKET ..... 108
	RUBRACA ..... 294
	RUXIENCE ..... 292
	RYBELSUS ..... 140
	RYBELSUS (FORMULATION R2)..... 140
	RYBREVANT ..... 22
	RYDAPT..... 212
	RYTELO..... 151
<b>S</b>	
	SAFETY INSULIN SYRINGES 29G X 1/2 .....
	SAFETY INSULIN SYRINGES 30G X 1/2 .....
	SAFETY INSULIN SYRINGES 30G X 5/16 .....
	SAFETY PEN NEEDLES 30G X 5 MM .....
	SAFETY PEN NEEDLES 30G X 8 MM .....
	sapropterin dihydrochloride oral tablet... 296
	SB ALCOHOL PREP PAD 70 %... 167, 174
	SB INSULIN SYRINGE 29G X 1/2 ..... 168, 174
	SB INSULIN SYRINGE 30G X 5/16 ... 168, 174
	SB INSULIN SYRINGE 31G X 5/16 ... 168, 174
	SCSEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG..... 31

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

SECURESAFE INSULIN SYRINGE 29G X 1/2.....	168, 174	SURE COMFORT INSULIN SYRINGE 30G X 5/16.....	168, 174
SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM.....	168, 174	SURE COMFORT INSULIN SYRINGE 31G X 1/4.....	168, 174
SELARSDI .....	373, 374, 375, 376	SURE COMFORT INSULIN SYRINGE 31G X 5/16.....	168, 174
SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG.....	313	SURE COMFORT PEN NEEDLES 29G X 12.7MM .....	168, 174
SIGNIFOR .....	249	SURE COMFORT PEN NEEDLES 30G X 8 MM .....	168, 174
sildenafil citrate oral tablet 20 mg .....	305	SURE COMFORT PEN NEEDLES 31G X 5 MM .....	168, 174
SIRTURO .....	42	SURE COMFORT PEN NEEDLES 31G X 6 MM .....	168, 174
SKYRIZI.....	287, 288	SURE COMFORT PEN NEEDLES 31G X 8 MM .....	168, 174
SKYRIZI (150 MG DOSE) .....	287, 288	SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC).....	168, 174
SKYRIZI PEN .....	287, 288	SURE COMFORT PEN NEEDLES 32G X 4 MM (RX) .....	168, 174
SM ALCOHOL PREP PAD .....	168, 174	SURE COMFORT PEN NEEDLES 32G X 6 MM .....	168, 174
SM ALCOHOL PREP PAD 6-70 % EXTERNAL .....	168, 174	SURE-JECT INSULIN SYRINGE 31G X 5/16 .....	168, 174
SM ALCOHOL PREP PAD 70 %..	168, 174	SURE-PREP ALCOHOL PREP PAD 70 % .....	168, 174
SM GAUZE PAD 2 .....	168, 174	SURGICAL GAUZE SPONGE PAD 2	168, 174
sodium oxybate .....	308	SYMPAZAN.....	71
SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML .....	183	SYNRIBO .....	240
SOMAVERT.....	254	<b>T</b>	
sorafenib tosylate .....	315	TABRECTA .....	64
SPRAVATO (56 MG DOSE).....	116	tadalafil oral tablet 2.5 mg, 5 mg .....	321
SPRAVATO (84 MG DOSE).....	116	TAFINLAR ORAL CAPSULE .....	76
STELARA INTRAVENOUS .....	372	TAFINLAR ORAL TABLET SOLUBLE	77
STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML .....	370, 371	TAGRISSO .....	244
STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	370, 371	TALVEY.....	323
STERILE GAUZE PAD 2 .....	168, 174	TALZENNA .....	322
STERILE PAD 2.....	168, 174	TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG.....	222
STIVARGA .....	270	TAVNEOS.....	35
STRENSIQ .....	32, 33	TAZVERIK.....	325
sunitinib malate.....	319	TECHLITE INSULIN SYRINGE 29G X 1/2 .....	168, 174
SURE COMFORT ALCOHOL PREP PAD 70 % .....	168, 174	TECHLITE PEN NEEDLES 32G X 4 MM .....	168, 174
SURE COMFORT INSULIN SYRINGE 28G X 1/2.....	168, 174		
SURE COMFORT INSULIN SYRINGE 29G X 1/2.....	168, 174		
SURE COMFORT INSULIN SYRINGE 30G X 1/2.....	168, 174		

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

TECVAYLI.....	327	TREMFYA SUBCUTANEOUS	
TEPMETKO .....	330	SOLUTION PREFILLED SYRINGE 143,	144
TERIPARATIDE SUBCUTANEOUS		tretinoin external cream .....	350
SOLUTION PEN-INJECTOR 620		trientine hcl oral capsule 250 mg .....	362
MCG/2.48ML .....	331	TRUE COMFORT ALCOHOL PREP	
TERUMO INSULIN SYRINGE 29G X 1/2		PADS PAD 70 %.....	169, 174
.....	169, 174	TRUE COMFORT INSULIN SYRINGE	
testosterone cypionate intramuscular		30G X 1/2.....	169, 174
solution 100 mg/ml, 200 mg/ml, 200		TRUE COMFORT INSULIN SYRINGE	
mg/ml (1 ml) .....	333	30G X 5/16.....	169, 174
testosterone enanthate intramuscular		TRUE COMFORT INSULIN SYRINGE	
solution.....	334	31G X 5/16.....	169, 174
testosterone gel 1.62 % transdermal .....	332	TRUE COMFORT INSULIN SYRINGE	
testosterone transdermal gel 12.5 mg/act		32G X 5/16.....	169, 174
(1%), 20.25 mg/act (1.62%), 25		TRUE COMFORT PEN NEEDLES 31G X	
mg/2.5gm (1%), 50 mg/5gm (1%).....	332	5 MM .....	169, 174
tetrabenazine .....	335	TRUE COMFORT PEN NEEDLES 31G X	
TEVIMBRA.....	337	6 MM .....	169, 174
THALOMID .....	336	TRUE COMFORT PEN NEEDLES 32G X	
THERAGAUZE PAD 2.....	169, 174	4 MM .....	169, 174
TIBSOVO .....	181	TRUE COMFORT PRO ALCOHOL PREP	
TIVDAK .....	338	PAD 70 % .....	169, 174
TODAYS HEALTH PEN NEEDLES 29G		TRUE COMFORT PRO INSULIN SYR	
X 12MM.....	169, 174	30G X 1/2.....	169, 174
TODAYS HEALTH SHORT PEN		TRUE COMFORT PRO INSULIN SYR	
NEEDLE 31G X 8 MM .....	169, 174	30G X 5/16.....	169, 174
TOPCARE CLICKFINE PEN NEEDLES		TRUE COMFORT PRO INSULIN SYR	
31G X 6 MM.....	169, 174	31G X 5/16.....	169, 174
TOPCARE CLICKFINE PEN NEEDLES		TRUE COMFORT PRO INSULIN SYR	
31G X 8 MM.....	169, 174	32G X 5/16.....	169, 174
TOPCARE ULTRA COMFORT INS SYR		TRUE COMFORT PRO PEN NEEDLES	
29G X 1/2.....	169, 174	31G X 5 MM.....	169, 174
TOPCARE ULTRA COMFORT INS SYR		TRUE COMFORT PRO PEN NEEDLES	
30G X 5/16.....	169, 174	31G X 6 MM.....	169, 174
TOPCARE ULTRA COMFORT INS SYR		TRUE COMFORT PRO PEN NEEDLES	
31G X 5/16.....	169, 174	31G X 8 MM.....	169, 174
torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5		TRUE COMFORT PRO PEN NEEDLES	
mg .....	119	32G X 4 MM.....	169, 174
TRAZIMERA .....	359	TRUE COMFORT PRO PEN NEEDLES	
TRELSTAR MIXJECT .....	364	32G X 5 MM.....	169, 174
TREMFYA INTRAVENOUS.....	143, 144	TRUE COMFORT PRO PEN NEEDLES	
TREMFYA ONE-PRESS.....	143, 144	32G X 6 MM.....	169, 174
TREMFYA PEN SUBCUTANEOUS		TRUE COMFORT PRO PEN NEEDLES	
SOLUTION AUTO-INJECTOR 200		33G X 4 MM.....	169, 174
MG/2ML .....	143, 144		

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM.....	169, 174	ULTICARE INSULIN SAFETY SYR 29G X 1/2.....	170, 174
TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM.....	169, 174	ULTICARE INSULIN SYRINGE 28G X 1/2 .....	170, 174
TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM.....	169, 174	ULTICARE INSULIN SYRINGE 29G X 1/2 .....	170, 174
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM.....	170, 174	ULTICARE INSULIN SYRINGE 30G X 1/2 .....	170, 174
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM.....	170, 174	ULTICARE INSULIN SYRINGE 30G X 5/16 .....	170, 174
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM.....	170, 174	ULTICARE INSULIN SYRINGE 31G X 1/4 .....	170, 174
TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM.....	170, 174	ULTICARE INSULIN SYRINGE 31G X 5/16 .....	170, 174
TRUEPLUS INSULIN SYRINGE 28G X 1/2 .....	170, 174	ULTICARE MICRO PEN NEEDLES 32G X 4 MM.....	170, 174
TRUEPLUS INSULIN SYRINGE 29G X 1/2 .....	170, 174	ULTICARE MINI PEN NEEDLES 30G X 5 MM .....	170, 174
TRUEPLUS INSULIN SYRINGE 30G X 5/16 .....	170, 174	ULTICARE MINI PEN NEEDLES 31G X 6 MM .....	171, 174
TRUEPLUS INSULIN SYRINGE 31G X 5/16 .....	170, 174	ULTICARE MINI PEN NEEDLES 32G X 6 MM .....	171, 174
TRUEPLUS PEN NEEDLES 29G X 12MM .....	170, 174	ULTICARE PEN NEEDLES 29G X 12.7MM (OTC).....	171, 174
TRUEPLUS PEN NEEDLES 31G X 5 MM .....	170, 174	ULTICARE PEN NEEDLES 29G X 12.7MM (RX) .....	171, 174
TRUEPLUS PEN NEEDLES 31G X 6 MM .....	170, 174	ULTICARE PEN NEEDLES 31G X 5 MM .....	171, 174
TRUEPLUS PEN NEEDLES 31G X 8 MM .....	170, 174	ULTICARE SHORT PEN NEEDLES 30G X 8 MM.....	171, 174
TRUEPLUS PEN NEEDLES 32G X 4 MM .....	170, 174	ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC).....	171, 174
TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	139	ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX) .....	171, 174
TRUQAP ORAL TABLET .....	63	ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM.....	171, 174
TRUQAP TABLET THERAPY PACK 160 MG ORAL .....	63	ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM.....	171, 174
TRUXIMA .....	290	ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM.....	171, 174
TUKYSA ORAL TABLET 150 MG, 50 MG .....	365	ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM.....	171, 174
TURALIO .....	259	ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM.....	171, 174
TYENNE.....	344, 345, 346, 347	ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM.....	171, 174
TYMLOS .....	1		
U			
UBRELVY .....	366		

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2..... 171, 174	ULTRA FLO INSULIN SYRINGE 29G X 1/2 ..... 172, 174
ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16..... 171, 174	ULTRA FLO INSULIN SYRINGE 30G X 1/2 ..... 172, 174
ULTILET ALCOHOL SWABS PAD ... 171, 174	ULTRA FLO INSULIN SYRINGE 30G X 5/16 ..... 172, 174
ULTILET INSULIN SYRINGE 30G X 1/2 ..... 171, 174	ULTRA FLO INSULIN SYRINGE 31G X 5/16 ..... 172, 174
ULTILET INSULIN SYRINGE 30G X 5/16 ..... 171, 174	ULTRA THIN PEN NEEDLES 32G X 4 MM ..... 172, 174
ULTILET INSULIN SYRINGE 31G X 1/4 ..... 171, 174	ULTRACARE INSULIN SYRINGE 30G X 1/2 ..... 172, 174
ULTILET INSULIN SYRINGE 31G X 15/64 ..... 171, 174	ULTRACARE INSULIN SYRINGE 30G X 5/16 ..... 172, 174
ULTILET INSULIN SYRINGE 31G X 5/16 ..... 171, 174	ULTRACARE INSULIN SYRINGE 31G X 5/16 ..... 172, 174
ULTILET INSULIN SYRINGE SHORT 30G X 1/2..... 171, 174	ULTRACARE PEN NEEDLES 31G X 5 MM ..... 172, 174
ULTILET INSULIN SYRINGE SHORT 30G X 5/16..... 171, 174	ULTRACARE PEN NEEDLES 31G X 6 MM ..... 172, 174
ULTILET INSULIN SYRINGE SHORT 31G X 5/16..... 171, 174	ULTRACARE PEN NEEDLES 31G X 8 MM ..... 172, 174
ULTILET PEN NEEDLE 29G X 12.7MM ..... 171, 174	ULTRACARE PEN NEEDLES 32G X 4 MM ..... 172, 174
ULTILET PEN NEEDLE 31G X 5 MM 171, 174	ULTRACARE PEN NEEDLES 32G X 5 MM ..... 172, 174
ULTILET PEN NEEDLE 31G X 8 MM 171, 174	ULTRACARE PEN NEEDLES 32G X 6 MM ..... 172, 174
ULTILET PEN NEEDLE 32G X 4 MM 171, 174	ULTRACARE PEN NEEDLES 33G X 4 MM ..... 173, 174
ULTRA COMFORT INSULIN SYRINGE 30G X 5/16..... 171, 174	ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2..... 172, 174
ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM..... 171, 174	ULTRA-THIN II INS SYR SHORT 30G X 5/16 ..... 172, 174
ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM..... 171, 174	ULTRA-THIN II INS SYR SHORT 31G X 5/16 ..... 172, 174
ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM..... 172, 174	ULTRA-THIN II INSULIN SYRINGE 29G X 1/2..... 172, 174
ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM..... 172, 174	ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM..... 172, 174
ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2..... 172, 174	ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM..... 172, 174
ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16..... 172, 174	ULTRA-THIN II PEN NEEDLES 29G X 12.7MM ..... 172, 174
ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16..... 172, 174	UNIFINE OTC PEN NEEDLES 31G X 5 MM ..... 173, 174

**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

UNIFINE OTC PEN NEEDLES 32G X 4 MM .....	173, 174	V VALCHLOR.....	209
UNIFINE PEN NEEDLES 32G X 4 MM .....	173, 174	VALUE HEALTH INSULIN SYRINGE 29G X 1/2.....	173, 174
UNIFINE PENTIPS 29G X 12MM	173, 174	VANFLYTA.....	269
UNIFINE PENTIPS 31G X 6 MM.	173, 174	VANISHPOINT INSULIN SYRINGE 29G X 5/16.....	173, 174
UNIFINE PENTIPS 31G X 8 MM.	173, 174	VANISHPOINT INSULIN SYRINGE 30G X 3/16.....	173, 174
UNIFINE PENTIPS PLUS 29G X 12MM .....	173, 174	VANISHPOINT INSULIN SYRINGE 30G X 5/16.....	173, 174
UNIFINE PENTIPS PLUS 31G X 6 MM .....	173, 174	VEGZELMA.....	50
UNIFINE PENTIPS PLUS 32G X 4 MM .....	173, 174	VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	385
UNIFINE PROTECT PEN NEEDLE 30G X 5 MM .....	173, 174	VENCLEXTA STARTING PACK .....	385
UNIFINE PROTECT PEN NEEDLE 30G X 8 MM .....	173, 174	VEOZAH .....	125
UNIFINE PROTECT PEN NEEDLE 32G X 4 MM .....	173, 174	VERIFINE INSULIN PEN NEEDLE 29G X 12MM.....	173, 174
UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM.....	173, 174	VERIFINE INSULIN PEN NEEDLE 31G X 5 MM.....	173, 174
UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM.....	173, 174	VERIFINE INSULIN PEN NEEDLE 32G X 6 MM.....	173, 174
UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM.....	173, 174	VERIFINE INSULIN SYRINGE 29G X 1/2 .....	173, 174
UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM.....	173, 174	VERIFINE INSULIN SYRINGE 31G X 5/16 .....	173, 174
UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM.....	173, 174	VERIFINE PLUS PEN NEEDLE 31G X 5 MM .....	173, 174
UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM.....	173, 174	VERIFINE PLUS PEN NEEDLE 31G X 8 MM .....	173, 174
UNIFINE ULTRA PEN NEEDLE 31G X 5 MM .....	173, 174	VERIFINE PLUS PEN NEEDLE 32G X 4 MM .....	173, 174
UNIFINE ULTRA PEN NEEDLE 31G X 6 MM .....	173, 174	VERQUVO .....	386
UNIFINE ULTRA PEN NEEDLE 31G X 8 MM .....	173, 174	VERZENIO.....	6
UNIFINE ULTRA PEN NEEDLE 32G X 4 MM .....	173, 174	vigabatrin .....	387
UPTRAVI INTRAVENOUS.....	301	vigadrone.....	387
UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG .....	301	vigpoder .....	387
UPTRAVI TITRATION.....	301	VITRAKVI ORAL CAPSULE 100 MG, 25 MG .....	185
		VITRAKVI ORAL SOLUTION .....	185
		VIVIMUSTA .....	46
		VIZIMPRO .....	78
		VONJO .....	246
		VORANIGO .....	390
		voriconazole oral suspension reconstituted .....	391



**Sonder Health Plans Breathe Well (HMO C-SNP), Diabetes Wellness (HMO C-SNP),  
Heart Healthy (HMO C-SNP), Mind Matters (HMO C-SNP), and Renal Health (HMO  
CSNP) 2025 Prior Authorization (PA) Criteria**

VOSEVI.....	310	XPOVIO (60 MG ONCE WEEKLY) ORAL	
VOWST .....	121	TABLET THERAPY PACK 60 MG..	302
VP INSULIN SYRINGE 29G X 1/2 .....	173, 174	XPOVIO (60 MG TWICE WEEKLY)...	302
VUMERITY .....	91	XPOVIO (80 MG ONCE WEEKLY) ORAL	
VYALEV SUBCUTANEOUS SOLUTION		TABLET THERAPY PACK 40 MG..	302
12-240 MG/ML.....	129	XPOVIO (80 MG TWICE WEEKLY)...	302
VYLOY.....	395	XTANDI ORAL CAPSULE.....	109
<b>W</b>		XTANDI ORAL TABLET 40 MG, 80 MG	
WEBCOL ALCOHOL PREP LARGE PAD		.....	109
70 %.....	173, 174	XYOSTED .....	334
WEGMANS UNIFINE PENTIPS PLUS		<b>Y</b>	
31G X 8 MM.....	173, 174	YERVOY .....	179
WELIREG.....	45	YESINTEK.....	377, 378, 379, 380
WINREVAIR.....	316	YONSA.....	8
<b>X</b>		YUFLYMA (1 PEN).....	14, 15
XALKORI ORAL CAPSULE.....	74	YUFLYMA (2 SYRINGE).....	14, 15
XALKORI ORAL CAPSULE SPRINKLE		YUFLYMA-CD/UC/HS STARTER ..	14, 15
150 MG, 20 MG, 50 MG .....	75	<b>Z</b>	
XDEMVY .....	203	ZEJULA ORAL CAPSULE .....	226
XELJANZ.....	348, 349	ZEJULA ORAL TABLET.....	226
XELJANZ XR .....	348, 349	ZELBORAF .....	384
XERMELO .....	329	ZEVRX STERILE ALCOHOL PREP PAD	
XGEVA.....	86	PAD 70 % .....	173, 174
XIFAXAN ORAL TABLET 200 MG, 550		ZIIHERA.....	392
MG .....	279	ZIRABEV .....	52
XOLAIR .....	241, 243	ZOLADEX.....	142
XOSPATA .....	136	ZTALMY .....	134
XPOVIO (100 MG ONCE WEEKLY)		ZTLIDO .....	199
ORAL TABLET THERAPY PACK 50		ZURZUVAE ORAL CAPSULE 20 MG, 25	
MG .....	302	MG, 30 MG.....	396
XPOVIO (40 MG ONCE WEEKLY) ORAL		ZYDELIG .....	148
TABLET THERAPY PACK 10 MG, 40		ZYKADIA ORAL TABLET .....	66
MG .....	302	ZYNLONTA.....	201
XPOVIO (40 MG TWICE WEEKLY)		ZYNYZ.....	275
ORAL TABLET THERAPY PACK 40			
MG .....	302		